PATIENT_ID	START_DATE	STOP_DATE	EVENT_TYPE	TREATMENT_TYPE	TREATMENT_SUBTYPE	AGENT	NUMBER_OF_CYCLES	PRESCRIBED_DOSE	PRESCRIBED_DOSE_UNITS	REGIMEN_NUMBER	REGIMEN_INDICATION	REGIMEN_INDICATION_NOTES	MEASURE_OF_RESPONSE	CLINICAL_TRIAL_DRUG_CLASSIFICATION	ROUTE_OF_ADMINISTRATION	ROUTE_OF_ADMINISTRATION-2	THERAPY_ONGOING	TOTAL_DOSE	TOTAL_DOSE_UNITS	TX_ON_CLINICAL_TRIAL	ANATOMIC_TREATMENT_SITE	COURSE_NUMBER	NUMBER_OF_FRACTIONS	RADIATION_DOSAGE	RADIATION_TREATMENT_ONGOING	RADIATION_TYPE	RADIATION_UNITS	PHARM_REGIMEN	STEM_CELL_TRANSPLANTATION	STEM_CELL_TRANSPLANTATION_TYPE
TCGA-02-0001	92	278	Treatment	Chemotherapy		Isotretinoin	4		mg/m2		Adjuvant						No	75	mg/m2											
TCGA-02-0001	92	278	Treatment	Chemotherapy		Celecoxib	4		mg		Adjuvant						No	400	mg											
TCGA-02-0001	49	80	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		20	4500	No	External Beam	cgy			
TCGA-02-0003	49	94	Treatment	Chemotherapy		Tamoxifen	1		mg		Adjuvant						No	80	mg											
TCGA-02-0003	49	94	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0006	88	148	Treatment	Chemotherapy		Temozolomide	7		mg/m2		Adjuvant				PO			200	mg/m2											
TCGA-02-0006	21	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-02-0007	33	338	Treatment	Chemotherapy		Temozolomide	5		mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-02-0007	33	338	Treatment	Chemotherapy		Temozolomide	5		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0007	33	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6180	No	External Beam	cgy			
TCGA-02-0010	509	569	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO			200	mg/m2											
TCGA-02-0010	139	182	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-02-0011	20	145	Treatment	Chemotherapy		Temozolomide	4		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-02-0011	20	145	Treatment	Chemotherapy		Temozolomide	4		mg/m2		Other, Specify In Notes				PO		No	75	mg/m2											
TCGA-02-0011	20	61	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0014	2349		Treatment	Chemotherapy		Antineoplastons					Adjuvant						No													
TCGA-02-0014	2310	2347	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		18	3600	No	External Beam	cgy			
TCGA-02-0015	0		Treatment	Chemotherapy		Carmustine					Adjuvant				OTHER		No	1												
TCGA-02-0015	22	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0016	84	1041	Treatment	Chemotherapy		Temozolomide	30		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-02-0016	41	83	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		50	6000	No	External Beam	cgy			
TCGA-02-0021	72	191	Treatment	Chemotherapy		Temozolomide			mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-02-0021	27	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0023	-9	34	Treatment	Chemotherapy		Temozolomide	1		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0023	-9	34	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0024	152	701	Treatment	Chemotherapy		Temozolomide	18		mg/m2		Adjuvant				PO			3600	mg/m2											
TCGA-02-0024	33	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-02-0025	118	656	Treatment	Chemotherapy		Temozolomide	18		mg/m2/day		Adjuvant						No	200	mg/m2/day											
TCGA-02-0025	38	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0026	92	418	Treatment	Chemotherapy		Temozolomide	11		mg/m2/day		Adjuvant				PO		No	150	mg/m2/day											
TCGA-02-0026	28	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0027	27	256	Treatment	Chemotherapy		Temozolomide	6		mg/m2/day		Adjuvant				PO			1200	mg/m2/day											
TCGA-02-0027	27	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		50	6000	No	External Beam	cgy			
TCGA-02-0028	1939	2304	Treatment	Chemotherapy		Temozolomide	12		mg/m2		Adjuvant				PO			200	mg/m2											
TCGA-02-0028	951	993	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	5400		External Beam	cgy			
TCGA-02-0034	89	159	Treatment	Chemotherapy		Temozolomide	2		mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-02-0034	23	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0038	113	174	Treatment	Chemotherapy		Erlotinib	2		mg/day		Adjuvant				PO		No	150	mg/day											
TCGA-02-0038	29	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam				
TCGA-02-0043	297	359	Treatment	Chemotherapy		Lomustine	2		mg/m2		Adjuvant				IV		No	100	mg/m2											
TCGA-02-0043	69	115	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	5600	No	External Beam	cgy			
TCGA-02-0052	34	204	Treatment	Chemotherapy		Temozolomide	5		mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-02-0052	16	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0054	28	73	Treatment	Chemotherapy		Temozolomide	1		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0054	28	73	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0055	-112	0	Treatment	Chemotherapy		Temozolomide			mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0055	-112	0	Treatment	Chemotherapy		Temozolomide			mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-02-0055	-112	-67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0057	1		Treatment	Chemotherapy		Carmustine					Adjuvant				OTHER		No	1												
TCGA-02-0057	16	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6480	No	External Beam	cgy			
TCGA-02-0058	21	143	Treatment	Chemotherapy		Temozolomide	2		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0058	11	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0060	15	182	Treatment	Chemotherapy		Temozolomide	3		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-02-0060	15	182	Treatment	Chemotherapy		Temozolomide	3		mg/m2/day		Other, Specify In Notes				PO		No	600	mg/m2/day											
TCGA-02-0060	15	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0064	23	358	Treatment	Chemotherapy		Temozolomide	12		mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-02-0064	23	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0068	14	179	Treatment	Chemotherapy		Temozolomide	3		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0068	14	179	Treatment	Chemotherapy		Temozolomide	3		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-02-0068	14	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0069	15	945	Treatment	Chemotherapy		Temozolomide	24		mg/m2/day		Other, Specify In Notes				PO		No	75	mg/m2/day											
TCGA-02-0069	15	945	Treatment	Chemotherapy		Temozolomide	24		mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-02-0069	15	62	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0070	10	57	Treatment	Chemotherapy		Temozolomide	1		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0070	10	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0074	13	154	Treatment	Chemotherapy		Temozolomide	3		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0074	13	154	Treatment	Chemotherapy		Temozolomide	3		mg/m2/day		Other, Specify In Notes				PO		No	200	mg/m2/day											
TCGA-02-0074	13	62	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0075	16	36	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-02-0075	16	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0080	352	443	Treatment	Chemotherapy		Temozolomide	4		mg/m2/day		Adjuvant				PO		No	100	mg/m2/day											
TCGA-02-0080	16	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0083	69	404	Treatment	Chemotherapy		Temozolomide	11		mg/m2		Adjuvant				PO			200	mg/m2											
TCGA-02-0083	36	62	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-02-0085	740	786	Treatment	Chemotherapy		Temozolomide	1		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0085	740	786	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0086	13	85	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO			75	mg/m2											
TCGA-02-0086	13	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-02-0089	68	282	Treatment	Chemotherapy		Temozolomide	7		mg/m2		Adjuvant				PO		No	1400	mg/m2											
TCGA-02-0089	38	85	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0099	-260	-124	Treatment	Chemotherapy		Temozolomide	3		mg/m2/day		Adjuvant				PO		No	150	mg/m2/day											
TCGA-02-0099	-314	-271	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0102	158	402	Treatment	Chemotherapy		Lomustine	5		mg/m2/day		Adjuvant				IV		No	110	mg/m2/day											
TCGA-02-0102	158	402	Treatment	Chemotherapy		Procarbazine	5		mg/m2/day		Adjuvant				IV		No	60	mg/m2/day											
TCGA-02-0102	158	402	Treatment	Chemotherapy		Vincristine	5		mg/m2/day		Adjuvant				IV		No	1.4	mg/m2/day											
TCGA-02-0102	44	90	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	5700	No	External Beam	cgy			
TCGA-02-0104	1536	1786	Treatment	Chemotherapy		Temozolomide	9		mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-02-0104	1536	1786	Treatment	Chemotherapy		Temozolomide	9		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-02-0104	1536	1581	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0106	15	176	Treatment	Chemotherapy		Temozolomide	5		mg/m2/day		Adjuvant				PO		No	500	mg/m2/day											
TCGA-02-0106	15	176	Treatment	Chemotherapy		Temozolomide	5		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-02-0106	15	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam				
TCGA-02-0107	100	130	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO			200	mg/m2											
TCGA-02-0107	55	103	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0111	28	74	Treatment	Chemotherapy		Temozolomide	01		ug/m2		Adjuvant				PO		No	75	ug/m2											
TCGA-02-0111	28	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0113	1930	2628	Treatment	Chemotherapy		Temozolomide	24		mg/m2		Adjuvant				PO			4800	mg/m2											
TCGA-02-0113	286	333	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0114	84	197	Treatment	Chemotherapy		Vincristine	4		mg/m2/day		Adjuvant				IV		No	1.4	mg/m2/day											
TCGA-02-0114	75	197	Treatment	Chemotherapy		Lomustine	4		mg/m2/day		Adjuvant				IV		No	110	mg/m2/day											
TCGA-02-0114	75	197	Treatment	Chemotherapy		Procarbazine	4		mg/m2/day		Adjuvant				IV		No	60	mg/m2/day											
TCGA-02-0114	47	88	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0115	27	107	Treatment	Chemotherapy		Temozolomide					Adjuvant				PO		No													
TCGA-02-0115	27	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0116	53	388	Treatment	Chemotherapy		Temozolomide	12		mg/m2		Adjuvant				PO		No	900	mg/m2											
TCGA-02-0116	20	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-0289	93	182	Treatment	Chemotherapy		Lomustine	2		mg/m2		Adjuvant				IV		No	110	mg/m2											
TCGA-02-0289	93	182	Treatment	Chemotherapy		Vincristine	2		mg/m2/day		Adjuvant				IV		No	1.4	mg/m2/day											
TCGA-02-0289	93	182	Treatment	Chemotherapy		Procarbazine	2		mg/m2		Adjuvant				IV		No	60	mg/m2											
TCGA-02-0289	37	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam				
TCGA-02-0290	380	425	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam				
TCGA-02-0317	23	176	Treatment	Chemotherapy		Antineoplastons					Adjuvant																			
TCGA-02-0325	84	115	Treatment	Chemotherapy		Lomustine	1		mg/m2		Adjuvant				IV			110	mg/m2											
TCGA-02-0325	84	115	Treatment	Chemotherapy		Procarbazine	1		mg/m2		Adjuvant				IV			60	mg/m2											
TCGA-02-0325	84	115	Treatment	Chemotherapy		Vincristine	1		mg/m2		Adjuvant				IV			1.4	mg/m2											
TCGA-02-0325	19	64	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		28	5700		External Beam				
TCGA-02-0330	107	137	Treatment	Chemotherapy		Procarbazine	01		mg/m2		Adjuvant				IV			60	mg/m2											
TCGA-02-0330	107	137	Treatment	Chemotherapy		Vincristine	1		mg/m2		Adjuvant				IV			1.4	mg/m2											
TCGA-02-0330	107	137	Treatment	Chemotherapy		Lomustine	1		mg/m2		Adjuvant				IV			110	mg/m2											
TCGA-02-0330	45	90	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam				
TCGA-02-0332	99	230	Treatment	Chemotherapy		Lomustine	04		mg/m2		Adjuvant				IV			110	mg/m2											
TCGA-02-0332	99	230	Treatment	Chemotherapy		Procarbazine	4		mg/m2		Adjuvant				IV			60	mg/m2											
TCGA-02-0332	99	230	Treatment	Chemotherapy		Vincristine	4		mg/m2		Adjuvant				IV			1.4	mg/m2											
TCGA-02-0332	37	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam				
TCGA-02-0337	185	428	Treatment	Chemotherapy		Procarbazine	5		mg/m2/day		Adjuvant				IV		No	60	mg/m2/day											
TCGA-02-0337	185	428	Treatment	Chemotherapy		Vincristine	5		mg/m2/day		Adjuvant				IV		No	1.4	mg/m2/day											
TCGA-02-0337	185	434	Treatment	Chemotherapy		Lomustine	5		mg/m2/day		Adjuvant				IV		No	110	mg/m2/day											
TCGA-02-0337	33	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		28	5700	No	External Beam				
TCGA-02-0432	105	329	Treatment	Chemotherapy		Lomustine	6		mg/m2		Adjuvant				IV		No	100	mg/m2											
TCGA-02-0432	18	56	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam				
TCGA-02-0440	269	288	Treatment	Chemotherapy		Isotretinoin	01		ug/m2		Adjuvant				PO		No	75	ug/m2											
TCGA-02-0440	32	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-2466	28	71	Treatment	Chemotherapy		Temozolomide		75	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2466	72	102	Treatment	Chemotherapy		Temozolomide	1	150	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2466	28	71	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-2470	57	99	Treatment	Chemotherapy		Temozolomide		75	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2470	100	183	Treatment	Chemotherapy		Temozolomide	03	150	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2470	57	99	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-2483	95	466	Treatment	Chemotherapy		Temozolomide	12	150	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2483	53	94	Treatment	Chemotherapy		Temozolomide		75	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2483	53	94	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-2485	51	92	Treatment	Chemotherapy		Temozolomide		75	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2485	93	186	Treatment	Chemotherapy		Temozolomide	04	150	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2485	51	92	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-02-2486	130	230	Treatment	Chemotherapy		Isotretinoin	04	40	mg		Progression				PO		No		mg											
TCGA-02-2486	67	440	Treatment	Chemotherapy		Temozolomide	12	150	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2486	24	66	Treatment	Chemotherapy		Temozolomide		75	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-02-2486	24	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0119	53	58	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0125	880	941	Treatment	Chemotherapy		Irinotecan	2		mg		Progression				IV		No	566	mg											
TCGA-06-0125	1032	1352	Treatment	Chemotherapy		Tetrathiomolybdate	11		mg		Progression				PO		No	200	mg											
TCGA-06-0125	28	452	Treatment	Chemotherapy		Temozolomide	14		mg		Adjuvant				PO		No	300	mg											
TCGA-06-0125	28	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0125	830	833	Treatment	Radiation Therapy		Radiation 2					Recurrence										Primary Tumor Field		1	8000	No	Other	cgy			
TCGA-06-0125	1367	1367	Treatment	Radiation Therapy		Radiation 3					Recurrence										Primary Tumor Field		1	2000	No	Other	cgy			
TCGA-06-0127	21	64	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No		mg											
TCGA-06-0127	21	64	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0128	26	176	Treatment	Chemotherapy		Suramin	13				Adjuvant				PO		No													
TCGA-06-0128	601	649	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant						No	18	mg											
TCGA-06-0128	422	450	Treatment	Chemotherapy		Temozolomide	2		mg		Progression				PO		No	285	mg											
TCGA-06-0128	481	511	Treatment	Chemotherapy		Carmustine	1		mg		Progression				IV		No	382	mg											
TCGA-06-0128	207	391	Treatment	Chemotherapy		Irofulven	6		mg/m2		Progression				IV		No	11	mg/m2											
TCGA-06-0128	33	72	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0128	524	558	Treatment	Radiation Therapy		Radiation 2					Recurrence										Local Recurrence		25	5000	No	Other	cgy			
TCGA-06-0129	183	238	Treatment	Immunotherapy		Interleukin-13 + Pseudomonas Exotoxin			ml		Other, Specify In Notes						No	19.5	ml											
TCGA-06-0129	14	120	Treatment	Chemotherapy		Temozolomide	2				Other, Specify In Notes				PO		No													
TCGA-06-0129	14	53	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0130	74	280	Treatment	Chemotherapy		Temozolomide	08				Recurrence				PO		No													
TCGA-06-0130	74	122	Treatment	Radiation Therapy		Radiation 1					Recurrence										Local Recurrence			6120	No	External Beam	cgy			
TCGA-06-0133	14	53	Treatment	Chemotherapy		Nos	02		mg		Adjuvant				IV		No	200	mg											
TCGA-06-0133	79	430	Treatment	Chemotherapy		Irinotecan	10		mg		Progression				IV		No	263	mg											
TCGA-06-0133	14	53	Treatment	Chemotherapy		Temozolomide	02		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-06-0133	79	430	Treatment	Chemotherapy		Bevacizumab	10		mg		Progression				IV		No	927	mg											
TCGA-06-0133	14	53	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0137	637	637	Treatment	Chemotherapy		Carmustine	1				Recurrence				PO		No													
TCGA-06-0139	203	278	Treatment	Chemotherapy		Irinotecan	3		mg		Progression				IV		No	265	mg											
TCGA-06-0139	203	278	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	910	mg											
TCGA-06-0141	155	217	Treatment	Chemotherapy		Temozolomide	02	200	mg		Progression				PO		No		mg											
TCGA-06-0141	235	270	Treatment	Chemotherapy		Procarbazine	02	170	mg/day		Progression				PO		No	170	mg/day											
TCGA-06-0141	19	144	Treatment	Chemotherapy		Cai Nabit 9712	02	250	mg		Adjuvant				PO		No	250	mg											
TCGA-06-0141	19	61	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0145	24	50	Treatment	Chemotherapy		Pyrazinamide	01	871	mg		Adjuvant				IV		No	1524	mg											
TCGA-06-0146	16	315	Treatment	Chemotherapy		Carmustine	06	200	mg		Adjuvant				IV		No	480	mg											
TCGA-06-0146	16	315	Treatment	Chemotherapy		Cisplatin	06		mg		Adjuvant				IV		No		mg											
TCGA-06-0146	83	121	Treatment	Radiation Therapy		Radiation 1					Adjuvant	Other Information Not Documented In Medical Records									Primary Tumor Field				No	External Beam	cgy			
TCGA-06-0147	64	64	Treatment	Chemotherapy		Carmustine	01		mg		Adjuvant				PO		No		mg											
TCGA-06-0147	156	399	Treatment	Chemotherapy		Temozolomide	09		mg		Progression				PO		No		mg											
TCGA-06-0147	94	125	Treatment	Chemotherapy		Tamoxifen	02	10	mg/day		Progression				PO		No	10	mg/day											
TCGA-06-0147	0	0	Treatment	Chemotherapy		Carmustine	01	4	{wafer}		Adjuvant				INTUM		No	4	{wafer}											
TCGA-06-0147	11	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-06-0147	436	436	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		1	1800	No	Other	cgy			
TCGA-06-0148	25	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0150	335		Treatment	Chemotherapy		Carmustine											No													
TCGA-06-0150	495		Treatment	Chemotherapy		Procarbazine											No													
TCGA-06-0150	504		Treatment	Radiation Therapy		Radiation 2															Regional Site				No	External				
TCGA-06-0151	179	179	Treatment	Chemotherapy		Carmustine											No													
TCGA-06-0151	1330	1381	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0152	293	293	Treatment	Chemotherapy		Procarbazine	01	110	mg		Progression				PO		No	200	mg											
TCGA-06-0152	293	293	Treatment	Chemotherapy		Tamoxifen	01	10	mg		Progression				PO		No	20	mg											
TCGA-06-0152	263	293	Treatment	Chemotherapy		Carmustine	01	80	mg		Progression				PO		No		mg											
TCGA-06-0154	235	235	Treatment	Chemotherapy		Carmustine	01	8	{wafer}		Progression				INTUM		No	8	{wafer}											
TCGA-06-0154	160	191	Treatment	Chemotherapy		Carmustine	01		mg		Adjuvant						No		mg											
TCGA-06-0154	373		Treatment	Chemotherapy		Procarbazine		100	mg		Progression				PO		No	150	mg											
TCGA-06-0154	12	89	Treatment	Chemotherapy		Ci-980	04		mg		Adjuvant				IV		No		mg											
TCGA-06-0154	321	321	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence		1	1500	No	Other	cgy			
TCGA-06-0154	98	145	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-06-0155	144	236	Treatment	Chemotherapy		Carmustine	02		mg/m2		Adjuvant				IV		No	80	mg/m2											
TCGA-06-0155	9	52	Treatment	Targeted Molecular Therapy		Ci-980			mg/m2		Adjuvant				IV		No	400	mg/m2											
TCGA-06-0155	257	257	Treatment	Chemotherapy		Carmustine	1		{wafer}		Palliative				OTHER		No	8	{wafer}											
TCGA-06-0155	175	205	Treatment	Chemotherapy		Carmustine	02	80	mg		Adjuvant				PO		No		mg											
TCGA-06-0155	72	120	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5944	No	External Beam	cgy			
TCGA-06-0157	19	61	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0158	99	160	Treatment	Chemotherapy		Carmustine	02		mg		Progression				PO		No		mg											
TCGA-06-0158	33	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-06-0159	70	162	Treatment	Chemotherapy		Carmustine											No													
TCGA-06-0159	18	63	Treatment	Radiation Therapy		Radiation 1															Primary Tumor Field			6100	No	External	cgy			
TCGA-06-0160	33	63	Treatment	Chemotherapy		Ci-980											No													
TCGA-06-0160	190	242	Treatment	Chemotherapy		Carmustine											No													
TCGA-06-0160	277	277	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0160	86	128	Treatment	Radiation Therapy		Radiation 1															Primary Tumor Field		30	6000	No	External	cgy			
TCGA-06-0162	13	74	Treatment	Chemotherapy		Cai Nabit 9712	02				Adjuvant						No													
TCGA-06-0162	13	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam	cgy			
TCGA-06-0165	31	31	Treatment	Not Specified		Oxaliplatin											No													
TCGA-06-0165	122	153	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0165	122	153	Treatment	Targeted Molecular Therapy		Isotretinoin											No													
TCGA-06-0165	184	214	Treatment	Targeted Molecular Therapy		Imatinib											No													
TCGA-06-0165	47	103	Treatment	Radiation Therapy		Radiation 1															Primary Tumor Field		33	6040	No	External	cgy			
TCGA-06-0166	14	60	Treatment	Chemotherapy		Oxaliplatin	04	85	mg		Adjuvant				IV		No		mg											
TCGA-06-0166	77	137	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0167	24	68	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0167	77	197	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0167	258	289	Treatment	Chemotherapy		Bortezomib											No													
TCGA-06-0167	24	68	Treatment	Radiation Therapy		Radiation 1															Primary Tumor Field		30	6000	No	External	cgy			
TCGA-06-0168	28	76	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	150	mg											
TCGA-06-0168	488	519	Treatment	Chemotherapy		Carmustine	02	200	mg		Progression				PO		No	380	mg											
TCGA-06-0168	136	458	Treatment	Chemotherapy		Temozolomide	10	200	mg		Adjuvant				PO		No	380	mg											
TCGA-06-0168	537	537	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence		1	1800	No	Other	cgy			
TCGA-06-0168	28	76	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-06-0169	29	78	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No		mg											
TCGA-06-0169	-152	78	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		35	6000	No	External Beam	cgy			
TCGA-06-0171	231	273	Treatment	Chemotherapy		Carmustine	02	200	mg		Progression				IV		No	394	mg											
TCGA-06-0171	81	175	Treatment	Chemotherapy		Temozolomide	03	200	mg		Adjuvant				PO		No	400	mg											
TCGA-06-0171	36	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant	Per Site No Other Documentation Available									Primary Tumor Field				No	External Beam	cgy			
TCGA-06-0174	3	33	Treatment	Chemotherapy		Tipifarnib	01		mg		Adjuvant				PO		No		mg											
TCGA-06-0174	59	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant	Only 5 Fractions Of Radiation Before Treatment Ended									Primary Tumor Field		5	0951	No	External Beam	cgy			
TCGA-06-0175	15	22	Treatment	Chemotherapy		Tipifarnib	01				Adjuvant						No													
TCGA-06-0175	51	78	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		22	5900	No	External Beam	cgy			
TCGA-06-0176	127	584	Treatment	Chemotherapy		Temozolomide	12	200	mg/m2	01	Progression				PO		No	400	mg											
TCGA-06-0176	50	93	Treatment	Chemotherapy		Temozolomide	01	75	mg/m2	01	Progression				PO		No		mg											
TCGA-06-0176	50	93	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0178	2530		Treatment	Chemotherapy		Metformin	02	25	mg/kg	02	Progression				PO		No	2340	mg											
TCGA-06-0178	2572	2614	Treatment	Targeted Molecular Therapy		Bevacizumab	02	10	mg/kg	03	Progression				IV		No	909	mg											
TCGA-06-0178	51	95	Treatment	Chemotherapy		Temozolomide	01	200	mg/m2	01	Adjuvant				PO		No	400	mg											
TCGA-06-0178	113	751	Treatment	Chemotherapy		Temozolomide	24	200	mg/m2	01	Adjuvant				PO		No	400	mg											
TCGA-06-0178	51	95	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0184	93	670	Treatment	Chemotherapy		Temozolomide	22	200	mg/m2	01	Adjuvant				PO		No	440	mg											
TCGA-06-0184	23	72	Treatment	Chemotherapy		Temozolomide	01	75	mg/m2	01	Adjuvant				PO		No	150	mg											
TCGA-06-0184	1311	1646	Treatment	Chemotherapy		Temozolomide	12	75	mg/m2	02	Progression				PO		No	160	mg											
TCGA-06-0184	23	72	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	33	6100	No	External Beam	cgy			
TCGA-06-0184	1286	1300	Treatment	Radiation Therapy		Radiation 2					Progression										Distant Site	2	12	6000	No	Other	cgy			
TCGA-06-0185	2259		Treatment	Chemotherapy		Lomustine	04	110	mg/m2	06	Progression				PO		Yes		mg											
TCGA-06-0185	19	56	Treatment	Targeted Molecular Therapy		Arsenic Trioxide	12	0.25	mg/kg	01	Adjuvant				IV		No	17.25	mg											
TCGA-06-0185	98	249	Treatment	Chemotherapy		Temozolomide	06	200	mg/m2	01	Adjuvant				PO		No	370	mg											
TCGA-06-0185	1502	1636	Treatment	Chemotherapy		Cabozantinib	02	75	mg/day	03	Progression				PO		No	75	mg/day											
TCGA-06-0185	1986	2228	Treatment	Chemotherapy		Temozolomide	10	75	mg/m2	05	Progression				PO		No	145	mg											
TCGA-06-0185	739	1397	Treatment	Targeted Molecular Therapy		Bevacizumab	24	10	mg/kg	02	Progression				IV		No	689	mg											
TCGA-06-0185	739	1397	Treatment	Chemotherapy		Irinotecan	24	125	mg/m2	02	Progression				IV		No	232	mg											
TCGA-06-0185	1664		Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg/kg	04	Progression				IV		Yes	791	mg											
TCGA-06-0185	1670	1677	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-0185	18	57	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0188	334	949	Treatment	Chemotherapy		Erlotinib	22	75	mg/day	02	Progression				PO		No	75	mg/day											
TCGA-06-0188	334	949	Treatment	Chemotherapy		Sorafenib	22	200	mg/day	02	Progression				PO		No	200	mg/day											
TCGA-06-0188	965	1342	Treatment	Targeted Molecular Therapy		Bevacizumab	12	10	mg/kg	03	Progression				IV		No	864	mg											
TCGA-06-0188	1244	1337	Treatment	Chemotherapy		Temozolomide	02	75	mg/m2	4	Progression				PO		No	150	mg											
TCGA-06-0188	1342	1342	Treatment	Chemotherapy		Etoposide	01	75	mg/m2	05	Progression				PO		No	50	mg											
TCGA-06-0188	88	300	Treatment	Chemotherapy		Temozolomide	08	200	mg/m2	01	Adjuvant				PO		No	380	mg											
TCGA-06-0188	27	68	Treatment	Chemotherapy		Temozolomide	01	75	mg/m2	01	Adjuvant				PO		No	140	mg											
TCGA-06-0188	965	1230	Treatment	Chemotherapy		Irinotecan	08	125	mg/m2	03	Progression				IV		No	254	mg											
TCGA-06-0188	25	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0192	96	462	Treatment	Chemotherapy		Temozolomide	12	200	mg/m2	01	Adjuvant				PO		No	420	mg											
TCGA-06-0192	725	767	Treatment	Chemotherapy		Lomustine	02	160	mg	02	Progression				PO		No	160	mg											
TCGA-06-0192	816	1153	Treatment	Targeted Molecular Therapy		Bevacizumab	10	10	mg/kg	03	Progression				IV		No	873	mg											
TCGA-06-0192	18	60	Treatment	Chemotherapy		Temozolomide	01	75	mg/m2	01	Adjuvant				PO		No	150	mg											
TCGA-06-0192	919	980	Treatment	Chemotherapy		Temozolomide	02	75	mg/m2	04	Progression				PO		No	140	mg											
TCGA-06-0192	725	808	Treatment	Targeted Molecular Therapy		Cediranib	02	20	mg/day	02	Progression				PO		No	20	mg/day											
TCGA-06-0192	816	907	Treatment	Chemotherapy		Irinotecan	03	125	mg/m2	03	Progression				IV		No	262.5												
TCGA-06-0192	18	60	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0192	928	938	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-0195	169	200	Treatment	Chemotherapy		Etoposide	01				Progression						No													
TCGA-06-0195	169	200	Treatment	Chemotherapy		Carboplatin	01				Progression						No													
TCGA-06-0195	95	169	Treatment	Chemotherapy		Lomustine	02				Adjuvant						No													
TCGA-06-0195	95	169	Treatment	Chemotherapy		Procarbazine	02				Adjuvant						No													
TCGA-06-0195	95	169	Treatment	Chemotherapy		Vincristine	02				Adjuvant						No													
TCGA-06-0195	47	79	Treatment	Radiation Therapy		Radiation 1					Adjuvant	Per Site No Other Information Available In Medical Records									Primary Tumor Field				No	External Beam	cgy			
TCGA-06-0197	26	79	Treatment	Chemotherapy		Paclitaxel	03	175	mg		Adjuvant				IV		No		mg											
TCGA-06-0206	138	138	Treatment	Chemotherapy		Carmustine	01	200	mg		Adjuvant				IV		No		mg											
TCGA-06-0206	18	79	Treatment	Radiation Therapy		Radiation 1					Adjuvant	No Other Information Available In Medical Record									Primary Tumor Field				No	External Beam	cgy			
TCGA-06-0208	39	98	Treatment	Chemotherapy		Cisplatin	02		mg		Adjuvant				IV		No		mg											
TCGA-06-0208	39	98	Treatment	Chemotherapy		Carmustine	02				Adjuvant						No													
TCGA-06-0208	83	101	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			4800	No	External Beam	cgy			
TCGA-06-0210	123	148	Treatment	Radiation Therapy		Radiation 1					Adjuvant	Patient Stopped Radiation And Enrolled In Hospice									Primary Tumor Field		20	3270	No	External Beam	cgy			
TCGA-06-0211	149	210	Treatment	Chemotherapy		Carmustine	02		mg		Progression						No		mg											
TCGA-06-0211	25	44	Treatment	Chemotherapy		Ci-980	02	4.0	mg		Adjuvant				IV		No		mg											
TCGA-06-0211	221	221	Treatment	Chemotherapy		Carmustine	01	8	{wafer}		Progression				INTUM		No	8	{wafer}											
TCGA-06-0211	121	149	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-06-0214	18	52	Treatment	Chemotherapy		Ci-980	02		mg		Adjuvant				IV		No		mg											
TCGA-06-0214	119	331	Treatment	Chemotherapy		Carmustine	06	200	mg		Progression				PO		No		mg											
TCGA-06-0214	331	453	Treatment	Chemotherapy		Tamoxifen	04	10	mg/day		Progression				PO		No	10	mg/day											
TCGA-06-0214	66	109	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-06-0216	586	586	Treatment	Chemotherapy		Carmustine	01		meq		Progression				PO		No		meq											
TCGA-06-0216	36	97	Treatment	Chemotherapy		Ci-980	04				Adjuvant						No													
TCGA-06-0216	250	463	Treatment	Chemotherapy		Temozolomide	07	150	mg		Progression				PO		No	280	mg											
TCGA-06-0216	128	159	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0216	215	215	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		1	800	No	Other	cgy			
TCGA-06-0221	280	280	Treatment	Chemotherapy		Carmustine	01	6	{wafer}		Progression				INTUM		No	6	{wafer}											
TCGA-06-0221	502	532	Treatment	Chemotherapy		Carmustine	01				Progression						No													
TCGA-06-0221	318	471	Treatment	Chemotherapy		Temozolomide	06		mg		Progression				PO		No		mg											
TCGA-06-0221	502	532	Treatment	Chemotherapy		6-O-Benzylguanine	01				Progression						No													
TCGA-06-0221	14	259	Treatment	Chemotherapy		Cai Nabit 9712	08	250	mg/day		Adjuvant				PO		No	250	mg/day											
TCGA-06-0221	280	285	Treatment	Chemotherapy		6-O-Benzylguanine	01				Progression				IV		No													
TCGA-06-0221	471	502	Treatment	Chemotherapy		Vatalanib	01				Progression						No													
TCGA-06-0221	379	471	Treatment	Chemotherapy		13-Cis-12-(3'-Carboxyphenyl)Retinoic Acid	04		mg		Progression				PO		No		mg											
TCGA-06-0221	21	65	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0240	34	65	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0240	36	320	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0240	36	320	Treatment	Chemotherapy		Cilengitide											No													
TCGA-06-0240	337	407	Treatment	Chemotherapy		Irinotecan											No													
TCGA-06-0240	337	589	Treatment	Targeted Molecular Therapy		Bevacizumab											No													
TCGA-06-0240	435	511	Treatment	Chemotherapy		Temozolomide											No													
TCGA-06-0240	547	589	Treatment	Chemotherapy		Carboplatin											No													
TCGA-06-0240	34	65	Treatment	Radiation Therapy		Radiation 1															Primary Tumor Field		30	6000	No	External	cgy			
TCGA-06-0240	420	432	Treatment	Radiation Therapy		Radiation 2															Local Recurrence		6	3600	No		cgy			
TCGA-06-0241	203	799	Treatment	Targeted Molecular Therapy		Bevacizumab	20	10	mg/kg	02	Progression				IV		No	773	mg											
TCGA-06-0241	1043	1435	Treatment	Targeted Molecular Therapy		Bevacizumab	10	10	mg/kg	05	Progression				IV		No	822	mg											
TCGA-06-0241	477	728	Treatment	Chemotherapy		Irinotecan	17	125	mg/m2	02	Progression				IV		No	773	mg											
TCGA-06-0241	15	81	Treatment	Targeted Molecular Therapy		Cilengitide	01	2000	mg	01	Adjuvant				IV		No	4000	mg											
TCGA-06-0241	84	192	Treatment	Targeted Molecular Therapy		Cilengitide	04	2000	mg	01	Adjuvant				IV		No	1600	mg											
TCGA-06-0241	1324	1383	Treatment	Chemotherapy		Temozolomide	03	100	mg/m2	03	Progression				PO		No	140	mg											
TCGA-06-0241	84	192	Treatment	Chemotherapy		Temozolomide	04	390	mg/day	01	Adjuvant				PO		No	390	mg/day											
TCGA-06-0241	15	81	Treatment	Chemotherapy		Temozolomide	01	140	mg/day	01	Adjuvant				PO		No	140	mg/day											
TCGA-06-0241	1267	1277	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-0241	15	56	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0394	158	281	Treatment	Chemotherapy		Carmustine	04	80	mg		Progression				IV		No		mg											
TCGA-06-0394	97	128	Treatment	Chemotherapy		Estramustine	01				Progression						No													
TCGA-06-0394	97	128	Treatment	Chemotherapy		Tioguanine	01				Progression						No													
TCGA-06-0394	97	128	Treatment	Chemotherapy		Vincristine	01				Progression						No													
TCGA-06-0394	38	83	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam	cgy			
TCGA-06-0397	126	176	Treatment	Chemotherapy		Procarbazine	02				Adjuvant						No													
TCGA-06-0397	126	176	Treatment	Chemotherapy		Lomustine	02				Adjuvant						No													
TCGA-06-0397	126	176	Treatment	Chemotherapy		Vincristine	02				Adjuvant						No													
TCGA-06-0397	104	115	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	Other	cgy			
TCGA-06-0409	75	149	Treatment	Chemotherapy		Hydroxyurea	01				Adjuvant				PO		No													
TCGA-06-0409	379	471	Treatment	Chemotherapy		9-Aminocamptothecin	06				Progression						No													
TCGA-06-0409	1845	2114	Treatment	Chemotherapy		Irinotecan	04	125	mg		Progression				IV		No		mg											
TCGA-06-0409	1267	1267	Treatment	Chemotherapy		Carmustine	01		{wafer}		Progression				INTUM		No		{wafer}											
TCGA-06-0409	168	348	Treatment	Chemotherapy		Procarbazine	04				Adjuvant						No													
TCGA-06-0409	168	348	Treatment	Chemotherapy		Lomustine	04				Adjuvant						No													
TCGA-06-0409	1294	1779	Treatment	Chemotherapy		Tamoxifen	19	20	mg		Progression				PO		No	140	mg											
TCGA-06-0409	168	348	Treatment	Chemotherapy		Vincristine	04				Adjuvant						No													
TCGA-06-0409	1294	1628	Treatment	Chemotherapy		Procarbazine	12	50	mg		Progression				PO		No	100	mg											
TCGA-06-0409	75	149	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			5940	No	External Beam	cgy			
TCGA-06-0409	1809	1809	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		1	4000	No	Other	cgy			
TCGA-06-0412	106	137	Treatment	Chemotherapy		9-Aminocamptothecin	01				Adjuvant						No													
TCGA-06-0412	137	258	Treatment	Chemotherapy		Carmustine	02				Progression						No													
TCGA-06-0414	5	370	Treatment	Chemotherapy		Carmustine	4				Adjuvant				IV															
TCGA-06-0414	5	370	Treatment	Chemotherapy		Cisplatin	4				Adjuvant				IV															
TCGA-06-0414	5	5	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-06-0644	23	65	Treatment	Chemotherapy		Temozolomide	01	75	mg/m2	01	Adjuvant				PO		No	165	mg											
TCGA-06-0644	106	263	Treatment	Chemotherapy		Irinotecan	05	125	mg/m2	02	Progression				IV		No	270	mg											
TCGA-06-0644	96	333	Treatment	Targeted Molecular Therapy		Bevacizumab	07	10	mg/kg	02	Progression				IV		No	986	mg											
TCGA-06-0644	288	319	Treatment	Chemotherapy		Temozolomide	02	75	mg/m2	03	Progression				PO		No	190	mg											
TCGA-06-0644	280	291	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence	2	6	3600	No	Other	cgy			
TCGA-06-0644	23	65	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0650	26	67	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	110	mg											
TCGA-06-0650	516	560	Treatment	Chemotherapy		Irinotecan	02	125	mg		Progression				IV		No	200	mg											
TCGA-06-0650	586	678	Treatment	Chemotherapy		Temozolomide	03	100	mg		Progression				PO		No	160	mg											
TCGA-06-0650	389	431	Treatment	Chemotherapy		Azd	01	20	mg/day		Progression				PO		No	20	mg/day											
TCGA-06-0650	389	389	Treatment	Chemotherapy		Lomustine	01	160	mg		Progression				PO		No	160	mg											
TCGA-06-0650	516	658	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		No	614	mg											
TCGA-06-0650	96	355	Treatment	Chemotherapy		Temozolomide	04	150	mg		Adjuvant				PO		No	230	mg											
TCGA-06-0650	495	513	Treatment	Chemotherapy		Erlotinib	01	150	mg/day		Progression				PO		No	150	mg/day											
TCGA-06-0650	26	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-0650	678	684	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		3	2400	No	Other	cgy			
TCGA-06-0650	564	580	Treatment	Radiation Therapy		Radiation 3					Progression	Site Of Treatment Was Regional											6	3600	No	Other	cgy			
TCGA-06-0686	175	279	Treatment	Targeted Molecular Therapy		Gossypol	04	20	mg/day	02	Progression				PO		No	20	mg											
TCGA-06-0686	309	370	Treatment	Chemotherapy		Erlotinib	02	150	mg/day	03	Progression				PO		No	150	mg/day											
TCGA-06-0686	25	60	Treatment	Targeted Molecular Therapy		5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone	1	750	mg/m2	01	Adjuvant				IV		No	1875	mg											
TCGA-06-0686	25	66	Treatment	Targeted Molecular Therapy		5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone	01	150	mg/m2	01	Adjuvant				IV		No	1876	mg											
TCGA-06-0686	412	412	Treatment	Targeted Molecular Therapy		Bevacizumab	.5	10	mg/kg	04	Progression				IV		No	1182	mg											
TCGA-06-0686	384	412	Treatment	Chemotherapy		Irinotecan	1.5	125	mg/m2	04	Progression				IV		No	312	mg											
TCGA-06-0686	29	66	Treatment	Chemotherapy		Temozolomide	01	75	mg/m2	01	Adjuvant				PO		No	185	mg											
TCGA-06-0686	95	127	Treatment	Chemotherapy		Temozolomide	02	150	mg/m2	01	Adjuvant				PO		No	380	mg											
TCGA-06-0686	25	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0743	122	178	Treatment	Chemotherapy		Temozolomide	2	150	mg/m2	1	Adjuvant				PO		No	280	mg											
TCGA-06-0743	55	94	Treatment	Chemotherapy		Temozolomide	1	75	mg/m2	1	Adjuvant				PO		No	140	mg											
TCGA-06-0743	55	178	Treatment	Targeted Molecular Therapy		Cilengitide	2	500		1	Adjuvant				IV		No	500	mg											
TCGA-06-0743	203	704	Treatment	Targeted Molecular Therapy		Bevacizumab	16	10	mg/kg	2	Progression				IV		No	655	mg											
TCGA-06-0743	203	704	Treatment	Chemotherapy		Irinotecan	16	125	mg/m2	2	Progression				IV		No	224	mg											
TCGA-06-0743	55	94	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0744	81	111	Treatment	Chemotherapy		Temozolomide	01	75	mg/m2	01	Adjuvant				PO		No	190	mg											
TCGA-06-0744	111	477	Treatment	Chemotherapy		Temozolomide	12	150	mg/m2	01	Adjuvant				PO		No	380	mg											
TCGA-06-0744	81	111	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0875	89	454	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0875	18	60	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam				
TCGA-06-0876	98	271	Treatment	Chemotherapy		Temozolomide	5		mg		Adjuvant				PO			350	mg											
TCGA-06-0876	17	60	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0876	112	416	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0876	462	1146	Treatment	Targeted Molecular Therapy		Bevacizumab											No			No										
TCGA-06-0876	462	560	Treatment	Chemotherapy		Irinotecan											No			No										
TCGA-06-0876	17	60	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam				
TCGA-06-0876	446	446	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence	2	1	2000	No	Other	cgy			
TCGA-06-0877	13	17	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			100		External Beam				
TCGA-06-0878	78		Treatment	Chemotherapy		Irinotecan	5		mg		Adjuvant				IV		Yes	242	mg											
TCGA-06-0878	6	53	Treatment	Chemotherapy		Temozolomide	1		mg		Progression				PO			145	mg											
TCGA-06-0878	78		Treatment	Chemotherapy		Bevacizumab	5		mg		Adjuvant				IV		Yes	811	mg											
TCGA-06-0878	14	58	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam				
TCGA-06-0879	67		Treatment	Chemotherapy		Temozolomide	3		mg		Adjuvant				PO		Yes	200	mg											
TCGA-06-0879	1029	1029	Treatment	Chemotherapy		Lomustine											No			No										
TCGA-06-0879	1029	1205	Treatment	Targeted Molecular Therapy		Bevacizumab											No			No										
TCGA-06-0879	1085	1085	Treatment	Chemotherapy		Carboplatin											No			No										
TCGA-06-0879	84		Treatment	Targeted Molecular Therapy		Dc Vax (Dendritic Cell Vaccine)					Adjuvant						Yes													
TCGA-06-0879	19	60	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0879	117	435	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0879	84	580	Treatment	Targeted Molecular Therapy		Dc Vax (Dendritic Cell Vaccine)											No			No										
TCGA-06-0879	718	960	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0879	708	942	Treatment	Targeted Molecular Therapy		Dc Vax (Dendritic Cell Vaccine)											No			No										
TCGA-06-0879	998	1025	Treatment	Targeted Molecular Therapy		Cediranib											No			No										
TCGA-06-0879	998	1025	Treatment	Targeted Molecular Therapy		Cilengitide											No			No										
TCGA-06-0879	19	60	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam				
TCGA-06-0879	1091	1098	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-0881	150		Treatment	Chemotherapy		Bevacizumab	2		mg		Progression				IV		Yes	747.7	mg											
TCGA-06-0881	72	133	Treatment	Chemotherapy		Temozolomide	2		mg		Adjuvant				PO			140	mg											
TCGA-06-0881	150		Treatment	Chemotherapy		Irinotecan	2		mg		Adjuvant				IV		Yes	250	mg											
TCGA-06-0881	16	58	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam				
TCGA-06-0881	229	394	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence	2	5	3000	No	Other	cgy			
TCGA-06-0882	160		Treatment	Chemotherapy		Temozolomide			mg		Adjuvant				PO		Yes	300	mg											
TCGA-06-0882	17	60	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0882	113	205	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0882	236	403	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-0882	236	403	Treatment	Targeted Molecular Therapy		Bevacizumab											No			No										
TCGA-06-0882	447	487	Treatment	Chemotherapy		Irinotecan											No			No										
TCGA-06-0882	447	502	Treatment	Targeted Molecular Therapy		Bevacizumab											No			No										
TCGA-06-0882	502	502	Treatment	Chemotherapy		Carboplatin											No			No										
TCGA-06-0882	17	60	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam				
TCGA-06-0882	411	418	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-0882	17	60	Treatment	Radiation Therapy		Radiation 3					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-0939	378	665	Treatment	Targeted Molecular Therapy		Bevacizumab	10	10	mg/kg	02	Progression				IV		No	516	mg											
TCGA-06-0939	378	609	Treatment	Chemotherapy		Irinotecan	05	125	mg/m2	02	Progression				IV		No	175	mg											
TCGA-06-1084	89	209	Treatment	Chemotherapy		Temozolomide	04		mg		Adjuvant				PO		No	500	mg											
TCGA-06-1084	242	323	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		No	1455	mg											
TCGA-06-1084	301	331	Treatment	Chemotherapy		Temozolomide	01		mg/m2	03	Progression				PO		No	180	mg											
TCGA-06-1084	246	288	Treatment	Chemotherapy		Irinotecan	02	125	mg/m2	02	Progression				IV		No	337	mg											
TCGA-06-1084	445	546	Treatment	Chemotherapy		Doxorubicin	04	30	mg/m2	04	Progression				IV		No	81	mg											
TCGA-06-1084	242	323	Treatment	Targeted Molecular Therapy		Bevacizumab	03	10	mg	02	Progression				IV		No	1455	mg											
TCGA-06-1084	51	51	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		1	1200	No	Other	cgy			
TCGA-06-1084	16	57	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		60	6000	No	External Beam	cgy			
TCGA-06-1086	73	194	Treatment	Chemotherapy		Temozolomide	3		mg		Adjuvant				PO		No	400	mg											
TCGA-06-1086	17	59	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-1087	18	75	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-06-1087	18	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-1800	94	275	Treatment	Chemotherapy		Temozolomide	06		mg		Adjuvant				PO		No	400	mg											
TCGA-06-1800	35	78	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-1801	80	231	Treatment	Chemotherapy		Temozolomide	05	150	mg/m2		Adjuvant				PO		No	280	mg											
TCGA-06-1801	238	323	Treatment	Targeted Molecular Therapy		Bevacizumab	03	10	mg/kg	02	Progression				IV		No	850	mg											
TCGA-06-1801	238	323	Treatment	Chemotherapy		Irinotecan	03	125	mg/m2	02	Progression				INTRAVESICAL		No	227												
TCGA-06-1801	311	323	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-1802	429	429	Treatment	Chemotherapy		Temozolomide	01	75	mg/m2	03	Progression				PO		No	140	mg											
TCGA-06-1802	97	436	Treatment	Chemotherapy		Bevacizumab	11	10	mg/kg	02	Progression				IV		No	845	mg											
TCGA-06-1802	97	380	Treatment	Chemotherapy		Irinotecan	10	125	mg/m2	02	Progression				IV		No	646	mg											
TCGA-06-1802	411	420	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-1805	44		Treatment	Chemotherapy		Temozolomide	03		mg/m2		Adjuvant				PO		Yes	200	mg/m2											
TCGA-06-1805	35	76	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-1805	105	433	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-1805	35	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-1805	35	74	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-06-1806	26	64	Treatment	Chemotherapy		Temozolomide							stable disease				No			No										
TCGA-06-1806	81	256	Treatment	Chemotherapy		Temozolomide							clinical progressive disease				No			Yes										
TCGA-06-1806	81	256	Treatment	Chemotherapy		Veliparib							clinical progressive disease				No			Yes										
TCGA-06-1806	293	455	Treatment	Chemotherapy		Cabozantinib							clinical progressive disease				No			Yes										
TCGA-06-1806	26	64	Treatment	Radiation Therapy		Radiation 1							stable disease								Primary Tumor Field		30	60	No	External	gy			
TCGA-06-2558	29	71	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		28	59	No	External Beam	cgy			
TCGA-06-2559	28	49	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	100	mg											
TCGA-06-2559	28	49	Treatment	Radiation Therapy		Radiation 1					Palliative										Primary Tumor Field		15	45	No	Other	cgy			
TCGA-06-2561	171		Treatment	Chemotherapy		Irinotecan		125	mg		Progression				IV		Yes	201.25	mg											
TCGA-06-2561	171		Treatment	Chemotherapy		Bevacizumab		6	mg		Progression				IV		Yes	618	mg											
TCGA-06-2561	21	63	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	120	mg											
TCGA-06-2561	119	148	Treatment	Chemotherapy		Cabozantinib	02		mg		Progression				PO		No	125	mg											
TCGA-06-2561	478	492	Treatment	Chemotherapy		Carboplatin	01	6	auc	05	Progression				IV		No	571	mg											
TCGA-06-2561	348	471	Treatment	Chemotherapy		Temozolomide	03	25	mg/m2	04	Progression				PO		No	140	mg											
TCGA-06-2561	171	492	Treatment	Targeted Molecular Therapy		Bevacizumab	09	10	mg/kg	03	Progression				IV		No	618	mg											
TCGA-06-2561	171	325	Treatment	Chemotherapy		Irinotecan	05	125	mg/m2	03	Progression				IV		No	201.25	mg											
TCGA-06-2561	21	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-06-2561	352	358	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-2562	26	37	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	140	mg											
TCGA-06-2562	26	37	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		10	30	No	External Beam	cgy			
TCGA-06-2563	27	57	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	120	mg											
TCGA-06-2563	885	931	Treatment	Targeted Molecular Therapy		R04929097	02	20	mg/day	02	Progression				PO		No	20	mg/day											
TCGA-06-2563	934		Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg/kg	03	Progression				IV		Yes	549	mg											
TCGA-06-2563	27	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		23	46	No	External Beam	cgy			
TCGA-06-2563	566	576	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence	2	4	3200	No	Other	cgy			
TCGA-06-2565	90	151	Treatment	Chemotherapy		Temozolomide	02	200	mg		Adjuvant				PO		No	320	mg											
TCGA-06-2565	16	63	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	75	mg											
TCGA-06-2565	123	151	Treatment	Chemotherapy		Cabozantinib	01	75	mg		Adjuvant				PO		No	75	mg											
TCGA-06-2565	193		Treatment	Chemotherapy		Bevacizumab		10	mg		Progression				IV		Yes	550	mg											
TCGA-06-2565	193	406	Treatment	Targeted Molecular Therapy		Bevacizumab											No			No										
TCGA-06-2565	319	350	Treatment	Chemotherapy		Carboplatin											No			No										
TCGA-06-2565	363	455	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-06-2565	16	54	Treatment	Radiation Therapy		Radiation 1					Adjuvant	0.71 Cc									Primary Tumor Field		1	20	No	Other	cgy			
TCGA-06-2565	16	63	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-06-2565	193	193	Treatment	Radiation Therapy		Radiation 3					Progression										Local Recurrence		1	20	No	Other	cgy			
TCGA-06-2565	16	16	Treatment	Radiation Therapy		Radiation 4					Adjuvant	2.54 Cc									Primary Tumor Field		1	20	No	Other	cgy			
TCGA-06-2566	95	100	Treatment	Chemotherapy		Temozolomide	01	200	mg		Adjuvant				PO		No	295	mg											
TCGA-06-2566	30	69	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No		mg											
TCGA-06-2566	26	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-06-2570	19	61	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	130	mg											
TCGA-06-2570	80	402	Treatment	Chemotherapy		Temozolomide	12	200	mg		Adjuvant				PO		No	350	mg											
TCGA-06-2570	19	61	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-06-5408	154	337	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		No	680	mg											
TCGA-06-5408	95	154	Treatment	Chemotherapy		Iniparib	02	9.5	mg		Adjuvant				IV		No	652	mg											
TCGA-06-5408	95	154	Treatment	Chemotherapy		Temozolomide	2	200	mg/dl		Adjuvant				PO		No	360	mg/dl											
TCGA-06-5408	35	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-5411	96	218	Treatment	Chemotherapy		Temozolomide	4	200	mg/m2		Adjuvant				PO		No	300	mg/m2											
TCGA-06-5411	213	235	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		No	726	mg											
TCGA-06-5411	27	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-5411	151	151	Treatment	Radiation Therapy		Radiation 2					Progression	Stereotactic Radiosurgery 3.12 Cc's 18 Gy									Distant Recurrence		1	1800	No	Other	cgy			
TCGA-06-5412	71	71	Treatment	Chemotherapy		Temozolomide	1	200	mg/m2		Adjuvant				PO		No	300	mg/m2											
TCGA-06-5412	14	23	Treatment	Chemotherapy		Hydroxychloroquine	.5				Adjuvant				PO		No													
TCGA-06-5412	14	53	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-06-5413	261		Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		Yes	1059	mg											
TCGA-06-5413	87	179	Treatment	Chemotherapy		Temozolomide	3	200	mg		Adjuvant				PO		No	340	mg											
TCGA-06-5413	21	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-5414	41	124	Treatment	Chemotherapy		Hydroxychloroquine	3	600	mg		Adjuvant				PO		No	600	mg											
TCGA-06-5414	41	112	Treatment	Chemotherapy		Temozolomide	3	160	mg		Adjuvant				PO		No	160	mg											
TCGA-06-5414	41	84	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-5415	86		Treatment	Chemotherapy		Temozolomide		200	mg/m2		Adjuvant				PO		Yes	370	mg/m2											
TCGA-06-5415	48	90	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-5416	99		Treatment	Chemotherapy		Temozolomide		150	mg/m2		Adjuvant				PO		Yes	250	mg/m2											
TCGA-06-5416	36	77	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-5417	71		Treatment	Chemotherapy		Temozolomide		150	mg		Adjuvant				PO		Yes	225	mg											
TCGA-06-5417	20	64	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-5858	88	88	Treatment	Chemotherapy		Veliparib	01	10	mg		Adjuvant				PO		No	20	mg											
TCGA-06-5858	25	68	Treatment	Chemotherapy		Temozolomide	1	75	mg		Adjuvant				PO		No	150	mg											
TCGA-06-5858	196		Treatment	Chemotherapy		Carboplatin		3	mg		Progression				IV		Yes	274	mg											
TCGA-06-5858	196		Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		Yes	1014	mg											
TCGA-06-5858	25	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-5859	13	42	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	180	mg											
TCGA-06-5859	70		Treatment	Chemotherapy		Temozolomide		200	mg		Adjuvant				PO		Yes	460	mg											
TCGA-06-5859	13	28	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		12	3600	No	External Beam	cgy			
TCGA-06-6388	79	79	Treatment	Chemotherapy		Temozolomide	01	150	mg		Adjuvant				PO		No	300	mg											
TCGA-06-6388	21	63	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	125	mg											
TCGA-06-6388	120		Treatment	Chemotherapy		Temozolomide	01	75	mg		Progression				PO		Yes	150	mg											
TCGA-06-6388	120	120	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		No	886	mg											
TCGA-06-6388	21	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-6389	70		Treatment	Chemotherapy		Temozolomide	02	150	mg		Adjuvant				PO		Yes	240	mg											
TCGA-06-6389	32	73	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	140	mg											
TCGA-06-6389	32	73	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-6390	22	69	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No		mg											
TCGA-06-6390	96	96	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				IV		No		mg											
TCGA-06-6390	22	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-06-6695	68	127	Treatment	Chemotherapy		Temozolomide	02	150	mg		Adjuvant				PO		No	280	mg											
TCGA-06-6695	11	56	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	140	mg											
TCGA-06-6695	11	56	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-6697	232	275	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	160	mg											
TCGA-06-6697	359		Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		Yes	913	mg											
TCGA-06-6697	277	308	Treatment	Chemotherapy		Temozolomide	01	150	mg		Adjuvant				PO		No	320	mg											
TCGA-06-6697	308	338	Treatment	Chemotherapy		Temozolomide	01	75	mg/day		Progression				PO		No	140	mg/day											
TCGA-06-6697	232	275	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-6699	31		Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		Yes		mg											
TCGA-06-6699	31		Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				Yes	External Beam	cgy			
TCGA-06-6700	100		Treatment	Chemotherapy		Temozolomide		150	mg		Adjuvant				PO		Yes	300	mg											
TCGA-06-6700	22	77	Treatment	Targeted Molecular Therapy		Vandetanib		100	mg		Adjuvant				PO		No	400	mg											
TCGA-06-6700	27	60	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	150	mg											
TCGA-06-6700	27	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-6701	20	63	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	140	mg											
TCGA-06-6701	20	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-06-A5U0	31	74	Treatment	Chemotherapy		Temozolomide							clinical progressive disease				No			No										
TCGA-06-A5U0	122		Treatment	Chemotherapy		Lomustine											Yes			No										
TCGA-06-A5U0	129		Treatment	Chemotherapy		Procarbazine											Yes			No										
TCGA-06-A5U0	31	74	Treatment	Radiation Therapy		Radiation 1							radiographic progressive disease								Primary Tumor Field		30	6000	No	External	cgy			
TCGA-06-A6S0	18	28	Treatment	Radiation Therapy		Radiation 1							stable disease								Primary Tumor Field		4	32	No	External	gy			
TCGA-06-A6S1	8	45	Treatment	Chemotherapy		Temozolomide							clinical progressive disease				No			No										
TCGA-06-A6S1	8	45	Treatment	Radiation Therapy		Radiation 1							radiographic progressive disease								Primary Tumor Field		28	41.1	No	External	gy			
TCGA-06-A7TK	34	76	Treatment	Chemotherapy		Temozolomide							stable disease				No			No										
TCGA-06-A7TK	113		Treatment	Chemotherapy		Temozolomide											Yes			No										
TCGA-06-A7TK	342	419	Treatment	Chemotherapy		Lomustine							clinical progressive disease				No			No										
TCGA-06-A7TK	342	420	Treatment	Chemotherapy		Procarbazine							clinical progressive disease				No			No										
TCGA-06-A7TK	34	76	Treatment	Radiation Therapy		Radiation 1							stable disease								Primary Tumor Field		30	60	No	External	gy			
TCGA-06-A7TL	25	71	Treatment	Chemotherapy		Temozolomide							stable disease	chemotherapy			No			Yes										
TCGA-06-A7TL	25		Treatment	Not Specified		Pexidartinib							stable disease	targeted molecular therapy			Yes			Yes										
TCGA-06-A7TL	103		Treatment	Not Specified		Temozolomide							stable disease	chemotherapy			Yes			Yes										
TCGA-06-A7TL	209		Treatment	Chemotherapy		Lomustine											Yes			No										
TCGA-06-A7TL	209		Treatment	Chemotherapy		Procarbazine											Yes			No										
TCGA-06-A7TL	25	71	Treatment	Radiation Therapy		Radiation 1							stable disease								Primary Tumor Field		30	60	No	External	gy			
TCGA-08-0244	34	483	Treatment	Targeted Molecular Therapy		Tetrathiomolybdate			mg/day		Adjuvant						No	500	mg/day											
TCGA-08-0244	34	75	Treatment	Chemotherapy		Temozolomide					Adjuvant				PO															
TCGA-08-0244	34	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-08-0245	560	843	Treatment	Chemotherapy		Temozolomide	12		mg/m2		Progression				PO			150	mg/m2											
TCGA-08-0245	933	1065	Treatment	Chemotherapy		Carmustine	3		mg/m2		Progression				IV			150	mg/m2											
TCGA-08-0245	875	933	Treatment	Chemotherapy		Carmustine	01		mg/m2		Progression				PO			150	mg/m2											
TCGA-08-0245	878	933	Treatment	Hormone Therapy					mg		Progression							200	mg											
TCGA-08-0245	857	857	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence			1500		Other	cgy			
TCGA-08-0245	49	95	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		33	5940		External Beam	cgy			
TCGA-08-0245	467	522	Treatment	Radiation Therapy		Radiation 3					Progression										Local Recurrence		33	5940		External Beam	cgy			
TCGA-08-0246	35	103	Treatment	Chemotherapy		Temozolomide					Adjuvant				PO															
TCGA-08-0246	35	77	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-08-0344	2577	2850	Treatment	Chemotherapy		Carmustine	07				Progression				PO		No													
TCGA-08-0344	82	113	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-08-0344	2122	2122	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field			1550	No	Other	cgy			
TCGA-08-0344	120	120	Treatment	Radiation Therapy		Radiation 3					Adjuvant										Primary Tumor Field				No	Other				
TCGA-08-0345	45	52	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			0900	No	External Beam	cgy			
TCGA-08-0346	20	68	Treatment	Chemotherapy		Hydroxyurea	1		mg		Adjuvant				PO			300	mg											
TCGA-08-0346	20	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940		External Beam	cgy			
TCGA-08-0347	69	419	Treatment	Chemotherapy		Carmustine	06		mg		Progression				IV			400	mg											
TCGA-08-0347	422	465	Treatment	Chemotherapy		Procarbazine	01		mg/m2		Progression				PO			100	mg/m2											
TCGA-08-0347	486	605	Treatment	Chemotherapy		Carboplatin	04		mg		Progression				IV			350	mg											
TCGA-08-0347	10	54	Treatment	Chemotherapy		Hydroxyurea	01		mg/m2		Adjuvant				PO			300	mg/m2											
TCGA-08-0347	10	54	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		32	6400		External Beam	cgy			
TCGA-08-0347	63	63	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		1	4000		Other	cgy			
TCGA-08-0347	618	618	Treatment	Radiation Therapy		Radiation 3					Progression										Local Recurrence		1	2800		Other	cgy			
TCGA-08-0348	215	287	Treatment	Chemotherapy		Etoposide					Progression				IV		No													
TCGA-08-0348	215	287	Treatment	Targeted Molecular Therapy		Tamoxifen			mg/day		Progression						No	180	mg/day											
TCGA-08-0348	28	204	Treatment	Chemotherapy		Temozolomide					Adjuvant				PO		No													
TCGA-08-0348	28	136	Treatment	Targeted Molecular Therapy		Tetrathiomolybdate			mg/day		Adjuvant							1000	mg/day											
TCGA-08-0348	28	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-08-0348	218	218	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		1	1550	No	Other	cgy			
TCGA-08-0349	38	93	Treatment	Targeted Molecular Therapy		Tetrathiomolybdate			mg/day		Adjuvant						No	200	mg/day											
TCGA-08-0349	38	93	Treatment	Chemotherapy		Temozolomide	1		mg/m2/day		Adjuvant				PO		No	150	mg/m2/day											
TCGA-08-0349	105	183	Treatment	Chemotherapy		Carmustine	02		mg		Progression				PO			480	mg											
TCGA-08-0349	231	259	Treatment	Chemotherapy		Fenretinide	01		mg/day		Progression				PO			2600	mg/day											
TCGA-08-0349	38	85	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940		External Beam	cgy			
TCGA-08-0350	446	629	Treatment	Chemotherapy		Temozolomide	05				Progression				PO		No													
TCGA-08-0350	678	838	Treatment	Targeted Molecular Therapy		Erlotinib			mg/day		Progression						No	450	mg/day											
TCGA-08-0350	0	0	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		24	021	No	Implants	mci			
TCGA-08-0350	40	79	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		60	6540	No	External Beam	cgy			
TCGA-08-0351	72		Treatment	Chemotherapy		Temozolomide					Adjuvant				PO		No													
TCGA-08-0351	72	581	Treatment	Targeted Molecular Therapy		Tetrathiomolybdate			mg/day		Adjuvant						No		mg/day											
TCGA-08-0351	1594		Treatment	Targeted Molecular Therapy		Tetrathiomolybdate			mg		Progression						No	200	mg											
TCGA-08-0351	1594		Treatment	Chemotherapy		Temozolomide					Progression				PO		No													
TCGA-08-0351	84	126	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-08-0353	112	174	Treatment	Chemotherapy		Temozolomide	2		mg/m2/day		Adjuvant				PO		No	200	mg/m2/day											
TCGA-08-0353	6	76	Treatment	Chemotherapy		Temozolomide	1				Adjuvant				PO		No													
TCGA-08-0353	12	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-08-0353	192	196	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		5	4545	No	Other	cgy			
TCGA-08-0354	261	320	Treatment	Chemotherapy		Temozolomide	2		mg/day		Progression				PO		No	200	mg/day											
TCGA-08-0354	261	320	Treatment	Targeted Molecular Therapy		Erlotinib			mg/day		Progression						No	450	mg/day											
TCGA-08-0354	345	390	Treatment	Chemotherapy		Carmustine	2		mg		Progression				IV		No	380	mg											
TCGA-08-0354	28	253	Treatment	Chemotherapy		Poly-Iclc	8		ml		Adjuvant				OTHER		No	.8	ml											
TCGA-08-0354	345	393	Treatment	Chemotherapy		Isotretinoin	1		mg		Progression				IV		No	180	mg											
TCGA-08-0354	35	97	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-08-0355	88	498	Treatment	Chemotherapy		Temozolomide	14		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-08-0355	25	68	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO			75	mg/m2											
TCGA-08-0355	531	531	Treatment	Chemotherapy		Carmustine	1		mg		Progression				IV			210	mg											
TCGA-08-0355	582	582	Treatment	Chemotherapy		Carboplatin	1		mg		Progression				IV			590	mg											
TCGA-08-0355	573	607	Treatment	Targeted Molecular Therapy		Tamoxifen			mg		Progression							540	mg											
TCGA-08-0355	638	671	Treatment	Targeted Molecular Therapy		Enzastaurin					Progression																			
TCGA-08-0355	531	572	Treatment	Targeted Molecular Therapy		Tetrathiomolybdate			mg/day		Progression							1000	mg/day											
TCGA-08-0355	25	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field					External Beam	cgy			
TCGA-08-0356	101	447	Treatment	Chemotherapy		Temozolomide	12		mg		Adjuvant				PO		No	200	mg											
TCGA-08-0356	42	82	Treatment	Chemotherapy		Temozolomide	1		mg/day		Adjuvant				PO		No	75	mg/day											
TCGA-08-0356	42	84	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-08-0357	736	860	Treatment	Targeted Molecular Therapy		Sirolimus			mg/day		Progression						No	5	mg/day											
TCGA-08-0357	1097	1112	Treatment	Targeted Molecular Therapy		Cyclophosphamide			mg/day		Progression						Yes	100	mg/day											
TCGA-08-0357	875	985	Treatment	Chemotherapy		Etoposide	3		mg		Progression				PO		No	100	mg											
TCGA-08-0357	1007	1084	Treatment	Targeted Molecular Therapy		Sorafenib			mg/day		Progression						No	400	mg/day											
TCGA-08-0357	184	188	Treatment	Immunotherapy		Interleukin-13 + Pseudomonas Exotoxin			mg		Progression						No	36	mg											
TCGA-08-0357	1007	1084	Treatment	Targeted Molecular Therapy		Erlotinib			mg		Progression							100	mg											
TCGA-08-0357	471	688	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	475	mg											
TCGA-08-0357	93	136	Treatment	Targeted Molecular Therapy		Tetrathiomolybdate					Adjuvant						No													
TCGA-08-0357	93	136	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		No	75	mg											
TCGA-08-0357	736	860	Treatment	Immunotherapy		Interferon Alfa					Progression						No													
TCGA-08-0357	689	733	Treatment	Chemotherapy		Hydroxyurea	1		mg/day		Progression				PO		No	1000	mg/day											
TCGA-08-0357	736	860	Treatment	Chemotherapy		Lomustine	3		mg/m2		Progression				PO		No	110	mg/m2											
TCGA-08-0357	689	733	Treatment	Targeted Molecular Therapy		Imatinib			mg/day		Progression						No	1000	mg/day											
TCGA-08-0357	471	688	Treatment	Targeted Molecular Therapy		Irinotecan			mg		Progression						Yes	775	mg											
TCGA-08-0357	29	71	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		No	75	mg											
TCGA-08-0357	29	71	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6005	No	External Beam	cgy			
TCGA-08-0358	91	264	Treatment	Targeted Molecular Therapy		Erlotinib			mg/day		Adjuvant							200	mg/day											
TCGA-08-0358	33	75	Treatment	Chemotherapy		Temozolomide	01		mg/day		Adjuvant				PO			150	mg/day											
TCGA-08-0358	33	75	Treatment	Targeted Molecular Therapy		Erlotinib			mg/day		Adjuvant							150	mg/day											
TCGA-08-0358	341	467	Treatment	Immunotherapy		Hsppc-96 Vaccine			mg		Progression							0.4	mg											
TCGA-08-0358	491	548	Treatment	Chemotherapy		Lomustine	01		mg		Progression				PO			220	mg											
TCGA-08-0358	91	264	Treatment	Chemotherapy		Temozolomide	06		mg/m2		Adjuvant				PO			200	mg/m2											
TCGA-08-0358	288	293	Treatment	Immunotherapy		Interleukin-13 + Pseudomonas Exotoxin			mg		Progression							36	mg											
TCGA-08-0358	33	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-08-0375	41	83	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	mci			
TCGA-08-0375	181	181	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence			3500	No	Other	cgy			
TCGA-08-0380	293	330	Treatment	Chemotherapy		Etoposide	1		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-08-0380	275	330	Treatment	Targeted Molecular Therapy							Progression																			
TCGA-08-0380	161	193	Treatment	Chemotherapy		Carmustine	01		mg		Progression				IV			375	mg											
TCGA-08-0380	216	274	Treatment	Chemotherapy		Temozolomide			mg		Progression				PO			345	mg											
TCGA-08-0380	32	79	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	6600		External Beam	cgy			
TCGA-08-0386	29	76	Treatment	Targeted Molecular Therapy		Erlotinib			mg/day		Adjuvant						No	200	mg/day											
TCGA-08-0386	29	76	Treatment	Chemotherapy		Temozolomide	1		mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-08-0386	94	106	Treatment	Targeted Molecular Therapy		Erlotinib			mg/day		Adjuvant						No	200	mg/day											
TCGA-08-0386	95	427	Treatment	Chemotherapy		Temozolomide	11				Adjuvant				PO		No													
TCGA-08-0386	113	125	Treatment	Immunotherapy		Hsppc-96 Vaccine			mg		Progression						No	0.4	mg											
TCGA-08-0386	29	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-08-0389	39		Treatment	Chemotherapy		Temozolomide					Adjuvant				PO															
TCGA-08-0389	39		Treatment	Targeted Molecular Therapy		Nos					Adjuvant																			
TCGA-08-0389	39	100	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-08-0390	28	69	Treatment	Chemotherapy		Temozolomide	1		mg/day		Adjuvant				PO			150	mg/day											
TCGA-08-0390	105	132	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO			300	mg											
TCGA-08-0390	28	69	Treatment	Immunotherapy		Erlotinib			mg		Adjuvant				PO			100	mg											
TCGA-08-0390	105	132	Treatment	Immunotherapy		Erlotinib			mg		Adjuvant				PO			150	mg											
TCGA-08-0390	28	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			6000		External Beam	cgy			
TCGA-08-0510	35	90	Treatment	Chemotherapy		Temozolomide	2		mg/day		Adjuvant				PO		No	330	mg/day											
TCGA-08-0510	41	64	Treatment	Targeted Molecular Therapy		Tetrathiomolybdate			mg		Adjuvant						No		mg											
TCGA-08-0510	35	84	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-08-0512	28	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		60	6000	No	Combination	cgy			
TCGA-08-0514	36	79	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-08-0516	10	40	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-08-0516	171	171	Treatment	Radiation Therapy		Radiation 2					Progression														No	Implants				
TCGA-08-0517	1086	1359	Treatment	Chemotherapy		Procarbazine	06				Progression				PO		No													
TCGA-08-0517	16	58	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	5400	No	External Beam	cgy			
TCGA-08-0518	77	123	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-08-0520	175		Treatment	Chemotherapy		Temozolomide			mg/m2		Progression				PO			200	mg/m2											
TCGA-08-0520	152	152	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence		1	2000	No	Other	cgy			
TCGA-08-0520	24	79	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field			6000	No	External Beam	cgy			
TCGA-08-0521	27	63	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		No	140	mg											
TCGA-08-0521	99	126	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		No	300	mg											
TCGA-08-0521	27	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-08-0524	195	199	Treatment	Chemotherapy		Lomustine	1		mg		Progression				PO			170	mg											
TCGA-08-0524	195		Treatment	Targeted Molecular Therapy		Tetrathiomolybdate					Progression																			
TCGA-08-0524	73	123	Treatment	Targeted Molecular Therapy		Sch-63666			mg		Progression						No	150	mg											
TCGA-08-0524	138	189	Treatment	Targeted Molecular Therapy		Imatinib			mg		Progression							350	mg											
TCGA-08-0524	24	52	Treatment	Chemotherapy		Temozolomide	01		mg/day		Adjuvant				PO			120	mg/day											
TCGA-08-0524	24	52	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		20			External Beam				
TCGA-08-0525	6	39	Treatment	Chemotherapy		Temozolomide	01		mg/m2/day		Adjuvant				PO			75	mg/m2/day											
TCGA-08-0525	37	341	Treatment	Chemotherapy		Temozolomide					Adjuvant				PO															
TCGA-08-0525	370	402	Treatment	Targeted Molecular Therapy		Erlotinib					Progression																			
TCGA-08-0525	6	39	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			6000		External Beam	cgy			
TCGA-08-0529	106	328	Treatment	Chemotherapy		Temozolomide	7		mg		Adjuvant				PO		No	200	mg											
TCGA-08-0529	349	353	Treatment	Immunotherapy		Interleukin-13 + Pseudomonas Exotoxin			mg		Progression						No	36	mg											
TCGA-08-0529	41	84	Treatment	Chemotherapy		Temozolomide	1		mg/day		Adjuvant				PO		No	75	mg/day											
TCGA-08-0529	42	84	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	5976	No	External Beam	cgy			
TCGA-08-0531	27	69	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		No	135	mg											
TCGA-08-0531	102	198	Treatment	Chemotherapy		Temozolomide	4		mg		Adjuvant				PO		No	300	mg											
TCGA-08-0531	27	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-0615	28	28	Treatment	Chemotherapy		Carmustine	1		{wafer}		Adjuvant				INTUM		No	8	{wafer}											
TCGA-12-0615	278	383	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression						No	10	mg/kg											
TCGA-12-0615	102	172	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0615	195	278	Treatment	Chemotherapy		Irinotecan	2		mg/m2		Progression				IV		No	125	mg/m2											
TCGA-12-0615	195	278	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	10	mg											
TCGA-12-0616	407	433	Treatment	Targeted Molecular Therapy		Everolimus			mg		Progression						No	2.5	mg											
TCGA-12-0616	407	433	Treatment	Chemotherapy		Hydroxyurea	2		mg		Progression				PO		No	1000	mg											
TCGA-12-0616	260	348	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Adjuvant						No	10	mg/kg											
TCGA-12-0616	260	348	Treatment	Chemotherapy		Irinotecan	2		mg/m2		Adjuvant				IV		No	340	mg/m2											
TCGA-12-0616	407	433	Treatment	Targeted Molecular Therapy		Imatinib			mg		Progression						No	700	mg											
TCGA-12-0616	29	75	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-0616	362	407	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0616	106	259	Treatment	Chemotherapy		Temozolomide	4		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0616	29	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-12-0618	0	0	Treatment	Chemotherapy		Carmustine	01		{wafer}		Adjuvant				INTUM			8	{wafer}											
TCGA-12-0618	9	65	Treatment	Chemotherapy		Temozolomide	02		mg/m2		Adjuvant				PO			150	mg/m2											
TCGA-12-0618	24	65	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-12-0619	163	203	Treatment	Chemotherapy		Lomustine	1		mg/m2		Adjuvant				PO		No	82.5	mg/m2											
TCGA-12-0619	21	84	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0619	228	291	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Progression				PO		No	200	mg/m2											
TCGA-12-0619	443	571	Treatment	Chemotherapy		Etoposide	4		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0619	0	0	Treatment	Chemotherapy		Carmustine	1		{wafer}		Adjuvant				INTUM		No	8	{wafer}											
TCGA-12-0619	84	129	Treatment	Chemotherapy		Lomustine	1		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0619	291	350	Treatment	Chemotherapy		Etoposide	2		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0619	19	60	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		31	5800	No	External Beam	cgy			
TCGA-12-0620	21	68	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-0620	92	191	Treatment	Chemotherapy		Lomustine	2		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0620	21	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-0654	44	216	Treatment	Targeted Molecular Therapy		Mab I-131			mci		Adjuvant						No	120	mci											
TCGA-12-0654	44	216	Treatment	Targeted Molecular Therapy		81C6			mg		Adjuvant						No	20	mg											
TCGA-12-0654	89	133	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-0656	1817	1873	Treatment	Chemotherapy		Lomustine	1		mg/m2		Progression				PO		No	82.5	mg/m2											
TCGA-12-0656	22	22	Treatment	Targeted Molecular Therapy		Mab I-131			mci		Adjuvant						No	120	mci											
TCGA-12-0656	301	443	Treatment	Chemotherapy		Etoposide	2		mg/m2		Adjuvant				IV		No	37.5	mg/m2											
TCGA-12-0656	204	254	Treatment	Chemotherapy		Lomustine	1		mg/m2		Adjuvant				PO		No	55	mg/m2											
TCGA-12-0656	1758	1817	Treatment	Chemotherapy		Lomustine	1		mg/m2		Progression				PO		No	110	mg/m2											
TCGA-12-0656	1488	1758	Treatment	Chemotherapy		Temozolomide	6		mg/m2		Progression				PO		No	200	mg/m2											
TCGA-12-0656	135	204	Treatment	Chemotherapy		Lomustine	1		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0656	1873	1899	Treatment	Chemotherapy		Etoposide	01		mg/m2		Progression				IV		No	50	mg/m2											
TCGA-12-0656	22	22	Treatment	Targeted Molecular Therapy		81C6			mg		Adjuvant						No	20	mg											
TCGA-12-0656	70	114	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		31	5940	No	External Beam	cgy			
TCGA-12-0662	600	604	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Progression				PO			150	mg/m2											
TCGA-12-0662	278	334	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant							100	mg											
TCGA-12-0662	1041	1070	Treatment	Chemotherapy		Cyclophosphamide	01		mg		Progression				PO			100	mg											
TCGA-12-0662	876	876	Treatment	Chemotherapy		Carmustine	01		{wafer}		Progression				INTUM			8	{wafer}											
TCGA-12-0662	1133	1137	Treatment	Chemotherapy		Temozolomide			mg/m2		Progression				PO			10	mg/m2											
TCGA-12-0662	1133	1135	Treatment	Targeted Molecular Therapy		6-O-Benzylguanine			mg/m2		Progression							30	mg/m2											
TCGA-12-0662	1073	1090	Treatment	Immunotherapy		Tetrathiomolybdate			mg		Progression							400	mg											
TCGA-12-0662	1113	1161	Treatment	Immunotherapy		Celecoxib			mg		Progression				PO			400	mg											
TCGA-12-0662	1133	1135	Treatment	Targeted Molecular Therapy		6-O-Benzylguanine			mg/m2		Progression							120	mg/m2											
TCGA-12-0662	889	1028	Treatment	Chemotherapy		Irinotecan	03		mg/m2		Progression				IV			75	mg/m2											
TCGA-12-0662	120	221	Treatment	Chemotherapy		Lomustine	02		mg/m2		Adjuvant				PO			110	mg/m2											
TCGA-12-0662	340	417	Treatment	Chemotherapy		Lomustine	02		mg/m2		Adjuvant				PO			110	mg/m2											
TCGA-12-0662	627	844	Treatment	Chemotherapy		Temozolomide	07		mg/m2		Progression				PO			200	mg/m2											
TCGA-12-0662	224	278	Treatment	Chemotherapy		Etoposide	02		mg/m2		Adjuvant				PO			100	mg/m2											
TCGA-12-0662	1041	1070	Treatment	Chemotherapy		Etoposide	01		mg/m2		Progression				PO			50	mg/m2											
TCGA-12-0662	473	600	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant							200	mg											
TCGA-12-0662	417	473	Treatment	Chemotherapy		Etoposide	2		mg/m2		Adjuvant				PO			100	mg/m2											
TCGA-12-0662	47	88	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5800		External Beam	cgy			
TCGA-12-0670	601	722	Treatment	Immunotherapy		Celecoxib			mg/m2		Adjuvant				PO		No	125	mg/m2											
TCGA-12-0670	407	448	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Adjuvant				IV		No	125	mg/m2											
TCGA-12-0670	578	601	Treatment	Chemotherapy		Lomustine	01		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0670	448	516	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant				PO		No	200	mg											
TCGA-12-0670	601	722	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant				PO		No	200	mg											
TCGA-12-0670	211	288	Treatment	Chemotherapy		Lomustine	02		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0670	448	516	Treatment	Chemotherapy		Temozolomide	02		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0670	722	770	Treatment	Immunotherapy		Celecoxib			mg/m2		Adjuvant				PO		No	125	mg/m2											
TCGA-12-0670	43	77	Treatment	Targeted Molecular Therapy		Ch81C6			mg		Adjuvant						No	10	mg											
TCGA-12-0670	148	183	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0670	329	378	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Adjuvant				IV		No	125	mg/m2											
TCGA-12-0670	183	203	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0670	43	77	Treatment	Targeted Molecular Therapy		Mab I-131			mci		Adjuvant						No	80	mci											
TCGA-12-0670	578	601	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant				PO		No	200	mg											
TCGA-12-0670	448	516	Treatment	Immunotherapy		Celecoxib			mg/m2		Adjuvant				PO		No	125	mg/m2											
TCGA-12-0670	516	576	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant				PO		No	200	mg											
TCGA-12-0670	516	576	Treatment	Immunotherapy		Celecoxib			mg/m2		Adjuvant				PO		No	125	mg/m2											
TCGA-12-0670	516	576	Treatment	Chemotherapy		Lomustine	02		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0670	578	601	Treatment	Immunotherapy		Celecoxib			mg/m2		Adjuvant				PO		No	125	mg/m2											
TCGA-12-0670	327	378	Treatment	Immunotherapy		Celecoxib			mg/m2		Adjuvant				PO		No	125	mg/m2											
TCGA-12-0670	407	448	Treatment	Immunotherapy		Celecoxib			mg/m2		Adjuvant				PO		No	125	mg/m2											
TCGA-12-0670	77	122	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-12-0688	649	734	Treatment	Chemotherapy		Etoposide	3		mg		Progression				PO		No	25	mg											
TCGA-12-0688	501	597	Treatment	Chemotherapy		Temozolomide	3		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0688	96	179	Treatment	Chemotherapy		Lomustine	2		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0688	605	649	Treatment	Chemotherapy		Irinotecan	1		mg/m2		Progression				IV		No	340	mg/m2											
TCGA-12-0688	215	238	Treatment	Chemotherapy		Etoposide	1		mg/m2		Adjuvant				PO		No	37.5	mg/m2											
TCGA-12-0688	238	353	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant							100	mg											
TCGA-12-0688	238	353	Treatment	Chemotherapy		Etoposide	03		mg/m2		Adjuvant				PO			25	mg/m2											
TCGA-12-0688	25	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	6000	No	External Beam	cgy			
TCGA-12-0691	159	186	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Progression				PO		No	200	mg/m2											
TCGA-12-0691	117	159	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Progression				PO		No	150	mg/m2											
TCGA-12-0691	46	78	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-0692	14	45	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0703	215	302	Treatment	Chemotherapy		Irinotecan	3		mg/m2		Progression				IV		No	125	mg/m2											
TCGA-12-0703	13	125	Treatment	Targeted Molecular Therapy		Mab I-131			mci		Adjuvant				IV		No	120	mci											
TCGA-12-0703	322	530	Treatment	Chemotherapy		Carmustine	5		mg		Progression				IV		No	100	mg											
TCGA-12-0703	13	125	Treatment	Targeted Molecular Therapy		81C6			mg		Adjuvant						No	20	mg											
TCGA-12-0703	322	530	Treatment	Chemotherapy		Topotecan	05		mg/m2		Progression				IV		No	0.75	mg/m2											
TCGA-12-0769	250	341	Treatment	Chemotherapy		Irinotecan	2				Adjuvant				IV		No													
TCGA-12-0769	192	250	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0769	91	192	Treatment	Chemotherapy		Lomustine	2		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0769	33	78	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0769	33	78	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-0772	951	1112	Treatment	Chemotherapy		Lomustine	3		mg/m2		Progression				PO		No	110	mg/m2											
TCGA-12-0772	1307	1468	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression							10	mg/kg											
TCGA-12-0772	1468	1526	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression							10	mg											
TCGA-12-0772	1468	1526	Treatment	Targeted Molecular Therapy		Sirolimus			mg		Progression							10	mg											
TCGA-12-0772	1529	1616	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression							10	mg/kg											
TCGA-12-0772	1529	1616	Treatment	Chemotherapy		Etoposide	03		mg/m2		Progression				PO			50	mg/m2											
TCGA-12-0772	1468	1526	Treatment	Targeted Molecular Therapy		Erlotinib			mg/kg		Progression						No	150	mg/kg											
TCGA-12-0772	1112	1174	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0772	1307	1468	Treatment	Chemotherapy		Cyclophosphamide	05		mg		Progression				PO			100	mg											
TCGA-12-0772	120	489	Treatment	Chemotherapy		Etoposide	12		mg/m2		Adjuvant				PO		No	50	mg/m2											
TCGA-12-0772	670	951	Treatment	Chemotherapy		Irinotecan	6		mg/m2		Progression				IV		No	125	mg/m2											
TCGA-12-0772	1224	1265	Treatment	Chemotherapy		Lomustine	1		mg/m2		Progression				PO		No	82.5	mg/m2											
TCGA-12-0772	621	670	Treatment	Targeted Molecular Therapy		Ridaforolimus			mg		Progression						No	12.5	mg											
TCGA-12-0772	79	120	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0772	79	120	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		29	5940	No	External Beam	cgy			
TCGA-12-0773	773	875	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Progression				PO		No	150	mg/m2											
TCGA-12-0773	607	725	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant						No	100	mg											
TCGA-12-0773	1141	1274	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Progression				PO			50	mg/m2											
TCGA-12-0773	892	1015	Treatment	Chemotherapy		Lomustine	2		mg/m2		Progression				PO		No	82.5	mg/m2											
TCGA-12-0773	1015	1036	Treatment	Chemotherapy		Etoposide	1		mg/m2		Progression				PO		No	37.5	mg/m2											
TCGA-12-0773	55	56	Treatment	Targeted Molecular Therapy		81C6			mg		Adjuvant							10	mg											
TCGA-12-0773	1141	1274	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression							10	mg/kg											
TCGA-12-0773	55	56	Treatment	Targeted Molecular Therapy		81C6			mg		Adjuvant						No	10	mg											
TCGA-12-0773	1062	1141	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0773	326	431	Treatment	Chemotherapy		Irinotecan	2		mg/m2		Adjuvant				IV		No	125	mg/m2											
TCGA-12-0773	55	56	Treatment	Targeted Molecular Therapy		Mab I-131			mci		Adjuvant						No	61	mci											
TCGA-12-0773	431	516	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0773	1274	1311	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0773	516	607	Treatment	Chemotherapy		Lomustine	2		mg/m2		Adjuvant				PO		No	82.5	mg/m2											
TCGA-12-0773	150	245	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0773	235	326	Treatment	Chemotherapy		Lomustine	2		mg/m2		Adjuvant				PO		No	82.5	mg/m2											
TCGA-12-0773	90	140	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		35	6000	No	External Beam	cgy			
TCGA-12-0775	37	94	Treatment	Chemotherapy		Temozolomide	02		mg/m2		Adjuvant				PO			160	mg/m2											
TCGA-12-0775	117	158	Treatment	Chemotherapy		Lomustine	01		mg/m2		Progression				PO			90	mg/m2											
TCGA-12-0775	37	94	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		31	6000		External Beam	cgy			
TCGA-12-0776	33	74	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-0776	82	127	Treatment	Chemotherapy		Lomustine	1		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0776	140	275	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression				IV		No	10	mg/kg											
TCGA-12-0776	140	275	Treatment	Chemotherapy		Irinotecan	02		mg/m2		Progression				IV			340	mg/m2											
TCGA-12-0776	33	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-0778	250	329	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression				IV		No	10	mg/kg											
TCGA-12-0778	250	329	Treatment	Chemotherapy		Etoposide	03		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0778	89	147	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0778	22	68	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-0778	147	232	Treatment	Chemotherapy		Lomustine	2		mg		Adjuvant				PO		No	110	mg											
TCGA-12-0778	329	352	Treatment	Chemotherapy		Etoposide	01		mg/m2		Progression				PO			50	mg/m2											
TCGA-12-0778	355	385	Treatment	Targeted Molecular Therapy		Erlotinib			mg		Progression				PO			200	mg											
TCGA-12-0778	355	385	Treatment	Targeted Molecular Therapy		Sirolimus			mg/day		Progression				PO		No	15	mg/day											
TCGA-12-0778	329	352	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0778	355	385	Treatment	Targeted Molecular Therapy		Sirolimus			mg		Progression				PO		No	150	mg											
TCGA-12-0778	239	258	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		19	3500	No	External Beam	cgy			
TCGA-12-0778	363	363	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		1	1800	No	External Beam	cgy			
TCGA-12-0778	22	68	Treatment	Radiation Therapy		Radiation 3					Adjuvant										Primary Tumor Field		34	5940	No	External Beam	cgy			
TCGA-12-0778	363	363	Treatment	Radiation Therapy		Radiation 4					Progression										Local Recurrence		1	1500	No	External Beam	cgy			
TCGA-12-0780	21	77	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Progression				PO		No	75	mg/m2											
TCGA-12-0780	360	388	Treatment	Chemotherapy		Etoposide	1		mg/m2		Progression				IV		No	37.5	mg/m2											
TCGA-12-0780	111	350	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Adjuvant						No	10	mg/kg											
TCGA-12-0780	360	388	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression						No	10	mg/kg											
TCGA-12-0780	393	434	Treatment	Targeted Molecular Therapy		Erlotinib			mg		Progression						No	5	mg											
TCGA-12-0780	101	350	Treatment	Chemotherapy		Irinotecan	6		mg/m2		Adjuvant				IV		No	125	mg/m2											
TCGA-12-0780	393	434	Treatment	Targeted Molecular Therapy		Sirolimus			mg		Progression							150	mg											
TCGA-12-0780	21	77	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	6660	No	External Beam	cgy			
TCGA-12-0818	255	296	Treatment	Chemotherapy		Lomustine	01		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0818	26	47	Treatment	Targeted Molecular Therapy		81C6			mg		Adjuvant				OTHER		No	10	mg											
TCGA-12-0818	136	1643	Treatment	Chemotherapy		Lomustine	01		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0818	213	255	Treatment	Chemotherapy		Etoposide	01		mg/m2		Adjuvant				PO		No	50	mg/m2											
TCGA-12-0818	75	136	Treatment	Chemotherapy		Etoposide	02		mg/m2		Adjuvant				PO		No	50	mg/m2											
TCGA-12-0818	26	47	Treatment	Targeted Molecular Therapy		Mab I-131			mci		Adjuvant				OTHER		No	80	mci											
TCGA-12-0818	47	91	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		32	6400	No	External Beam	cgy			
TCGA-12-0819	376	442	Treatment	Chemotherapy		Carmustine	01		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0819	6	180	Treatment	Targeted Molecular Therapy		Mab I-131			mci		Adjuvant				OTHER		No	60	mci											
TCGA-12-0819	505	624	Treatment	Chemotherapy		Procarbazine	04		mg/m2		Progression				PO		No	150	mg/m2											
TCGA-12-0819	442	495	Treatment	Chemotherapy		Topotecan	01		mg/m2		Progression				IV		No	2.6	mg/m2											
TCGA-12-0819	258	376	Treatment	Chemotherapy		Carmustine	02		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0819	6	180	Treatment	Targeted Molecular Therapy		81C6			mg		Adjuvant				OTHER		No	9.9	mg											
TCGA-12-0819	180	219	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		33	6000	No	External Beam	cgy			
TCGA-12-0820	502	543	Treatment	Hormone Therapy		Tamoxifen			mg		Progression				PO		No	200	mg											
TCGA-12-0820	216	272	Treatment	Chemotherapy		Temozolomide	02		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0820	433	502	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Progression				IV		No	400	mg/m2											
TCGA-12-0820	502	543	Treatment	Chemotherapy		Etoposide	01		mg/m2		Progression				PO		No	62.5	mg/m2											
TCGA-12-0820	363	433	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Progression				IV		No	350	mg/m2											
TCGA-12-0820	-1	0	Treatment	Targeted Molecular Therapy		6-O-Benzylguanine			mg/m2		Adjuvant				IV		No	100	mg/m2											
TCGA-12-0820	300	341	Treatment	Chemotherapy		Carmustine	01		mg/m2		Progression				PO		No	13.5	mg/m2											
TCGA-12-0820	300	341	Treatment	Targeted Molecular Therapy		6-O-Benzylguanine			mg/m2		Progression						No	100	mg/m2											
TCGA-12-0820	342	363	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Progression				IV		No	300	mg/m2											
TCGA-12-0820	21	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-0821	123	165	Treatment	Chemotherapy		Lomustine	02		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0821	203	259	Treatment	Chemotherapy		Etoposide	02		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0821	271	296	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Progression				PO		No	190	mg/m2											
TCGA-12-0821	35	86	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		34	6120	No	External Beam	cgy			
TCGA-12-0822	126	175	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0822	625	625	Treatment	Targeted Molecular Therapy		Lonafarnib			mg		Progression				PO		No	150	mg											
TCGA-12-0822	625	652	Treatment	Targeted Molecular Therapy		Lonafarnib			mg		Progression				PO		No	300	mg											
TCGA-12-0822	588	624	Treatment	Chemotherapy		Etoposide	01		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0822	281	583	Treatment	Chemotherapy		Temozolomide	10		mg/m2		Progression				PO		No	200	mg/m2											
TCGA-12-0822	190	281	Treatment	Chemotherapy		Carmustine	02		mg/m2		Progression				PO		No	100	mg/m2											
TCGA-12-0822	190	281	Treatment	Targeted Molecular Therapy		O6-Benzylguanine			mg/m2		Progression				IV		No	40	mg/m2											
TCGA-12-0822	126	175	Treatment	Chemotherapy		Carmustine	01		mg/m2		Adjuvant				PO		No	40	mg/m2											
TCGA-12-0822	23	73	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	6020	No	External Beam	cgy			
TCGA-12-0827	181	258	Treatment	Chemotherapy		Lomustine	01		mg/m2		Adjuvant				PO		No	82.5	mg/m2											
TCGA-12-0827	615	746	Treatment	Hormone Therapy		Tamoxifen			mg		Adjuvant				PO		No	160	mg											
TCGA-12-0827	34	76	Treatment	Targeted Molecular Therapy		81C6			mg		Adjuvant						No	20	mg											
TCGA-12-0827	34	76	Treatment	Targeted Molecular Therapy		Mab I-131			mci		Adjuvant						No	120	mci											
TCGA-12-0827	137	181	Treatment	Chemotherapy		Lomustine	01		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-0827	390	434	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Adjuvant				IV		No	410	mg/m2											
TCGA-12-0827	466	615	Treatment	Chemotherapy		Temozolomide	04		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0827	350	390	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0827	258	350	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-12-0827	76	127	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-12-0828	28	152	Treatment	Chemotherapy		Temozolomide	04		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0828	161	195	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		25	4600	No	External Beam	cgy			
TCGA-12-0829	115	473	Treatment	Immunotherapy		Attac			ml		Adjuvant						No	1	ml											
TCGA-12-0829	16	64	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-0829	95	473	Treatment	Chemotherapy		Temozolomide	06		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-0829	572	599	Treatment	Chemotherapy		Irinotecan	01		mg/m2		Progression				IV		No	125	mg/m2											
TCGA-12-0829	572	599	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression						No	10	mg/kg											
TCGA-12-0829	474	571	Treatment	Chemotherapy		Temozolomide	04		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-0829	474	571	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression				IV		No	10	mg/kg											
TCGA-12-0829	16	64	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-1088	3779	3821	Treatment	Chemotherapy		Lomustine	01		mg/m2		Adjuvant				PO		No	82.5	mg/m2											
TCGA-12-1088	3735	3779	Treatment	Chemotherapy		Lomustine	01		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-1088	3667	3716	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-12-1089	105	147	Treatment	Chemotherapy		Lomustine	01		mg/m2		Adjuvant				PO		No	110	mg/m2											
TCGA-12-1089	33	77	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	6000	No	External Beam	cgy			
TCGA-12-1090	46	46	Treatment	Chemotherapy		Carmustine	01		{wafer}		Adjuvant				INTUM			8	{wafer}											
TCGA-12-1090	126	191	Treatment	Chemotherapy		Tetrathiomolybdate	02		mg		Progression				PO			800	mg											
TCGA-12-1090	126	191	Treatment	Chemotherapy		Cyclophosphamide	02		mg		Progression				PO			100	mg											
TCGA-12-1090	71	113	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		32	6000		External Beam				
TCGA-12-1091	143	169	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Progression				PO			200	mg/m2											
TCGA-12-1091	453	484	Treatment	Hormone Therapy		Tamoxifen			mg		Progression				PO			160	mg											
TCGA-12-1091	229	287	Treatment	Chemotherapy		Lomustine	1		mg/m2		Progression				PO			90	mg/m2											
TCGA-12-1091	358	453	Treatment	Chemotherapy		Etoposide	2		mg/m2		Progression				PO			100	mg/m2											
TCGA-12-1091	179	206	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Progression				PO			150	mg/m2											
TCGA-12-1091	521	691	Treatment	Chemotherapy		Temozolomide	3		mg/m2		Progression				PO			300	mg/m2											
TCGA-12-1091	521	691	Treatment	Hormone Therapy		Tamoxifen			mg		Progression				PO			120	mg											
TCGA-12-1091	484	521	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Progression				PO			125	mg/m2											
TCGA-12-1091	358	453	Treatment	Hormone Therapy		Tamoxifen			mg		Progression				PO			160	mg											
TCGA-12-1091	484	521	Treatment	Hormone Therapy		Tamoxifen			mg		Progression				PO			160	mg											
TCGA-12-1091	288	330	Treatment	Chemotherapy		Lomustine	1		mg/m2		Progression				PO			80	mg/m2											
TCGA-12-1091	453	484	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Progression				PO			150	mg/m2											
TCGA-12-1091	819	926	Treatment	Chemotherapy		Etoposide	2		mg/m2		Progression				PO			100	mg/m2											
TCGA-12-1091	331	358	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Progression				PO			200	mg/m2											
TCGA-12-1091	67	112	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		33	6000		External Beam	cgy			
TCGA-12-1092	232	367	Treatment	Chemotherapy		Temozolomide	04		mg/m2		Adjuvant				PO		No	50	mg/m2											
TCGA-12-1092	119	204	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Adjuvant				IV		No	10	mg/kg											
TCGA-12-1092	205	232	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-1092	119	204	Treatment	Chemotherapy		Temozolomide	03		mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-12-1092	46	96	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-1092	551	637	Treatment	Chemotherapy		Temozolomide	03		mg/m2		Adjuvant				PO		No	50	mg/m2											
TCGA-12-1092	460	551	Treatment	Targeted Molecular Therapy		Sirolimus			mg		Adjuvant				PO		No	5	mg											
TCGA-12-1092	368	460	Treatment	Chemotherapy		Irinotecan	02		mg/m2		Adjuvant				IV		No	125	mg/m2											
TCGA-12-1092	460	551	Treatment	Targeted Molecular Therapy		Erlotinib			mg		Adjuvant				PO		No	150	mg											
TCGA-12-1092	46	96	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	6000	No	External Beam	cgy			
TCGA-12-1093	339	364	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Progression				PO			50	mg/m2											
TCGA-12-1093	38	79	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO			75	mg/m2											
TCGA-12-1093	126	317	Treatment	Immunotherapy		Attac			ml		Adjuvant				PO			1	ml											
TCGA-12-1093	339	364	Treatment	Chemotherapy		2-Methoxyestradiol	1		mg		Progression				PO			6000	mg											
TCGA-12-1093	105	317	Treatment	Chemotherapy		Temozolomide	5		mg/m2		Adjuvant				PO			1000	mg/m2											
TCGA-12-1093	38	79	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000		External Beam	cgy			
TCGA-12-1094	286	336	Treatment	Chemotherapy		Temozolomide	02		mg/m2		Progression				PO		No	100	mg/m2											
TCGA-12-1094	231	269	Treatment	Chemotherapy		Lomustine			mg/m2		Progression				PO		No	125	mg/m2											
TCGA-12-1094	141	213	Treatment	Chemotherapy		Temozolomide	3		mg/m2		Adjuvant				PO		No	600	mg/m2											
TCGA-12-1094	104	215	Treatment	Immunotherapy		Dactinomycin					Adjuvant				PO		No	1												
TCGA-12-1094	286	336	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/m2		Progression				PO		No	10	mg/m2											
TCGA-12-1094	18	67	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO			75	mg/m2											
TCGA-12-1094	18	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		34	6120	No	External Beam	cgy			
TCGA-12-1095	404	412	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/m2		Progression				IV		No	10	mg/m2											
TCGA-12-1095	34	82	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-1095	95	286	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/m2		Progression						No	10	mg/m2											
TCGA-12-1095	404	412	Treatment	Chemotherapy		Etoposide	01		mg/m2		Progression				PO		No	37.5	mg/m2											
TCGA-12-1095	291	370	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/m2		Progression				IV		No	10	mg/m2											
TCGA-12-1095	112	286	Treatment	Chemotherapy		Irinotecan	04		mg/m2		Progression				IV		No	340	mg/m2											
TCGA-12-1095	34	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-12-1096	63	101	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO			75	mg/m2											
TCGA-12-1096	130	201	Treatment	Chemotherapy		Temozolomide	2		mg/m2		Progression				PO		Yes	300	mg/m2											
TCGA-12-1096	202	277	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/m2		Adjuvant				IV		No		mg/m2											
TCGA-12-1096	202	277	Treatment	Chemotherapy		Irinotecan	2		mg/m2		Adjuvant				IV		No	250	mg/m2											
TCGA-12-1096	63	104	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-1097	110	166	Treatment	Chemotherapy		Temozolomide	02		mg/m2		Progression				PO		No	200	mg/m2											
TCGA-12-1097	177	343	Treatment	Targeted Molecular Therapy		Rilotumumab			mg/kg		Progression				IV		No	10	mg/kg											
TCGA-12-1097	351	385	Treatment	Chemotherapy		Etoposide	01		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-1097	49	96	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-1097	351	385	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Progression				PO		No	50	mg/m2											
TCGA-12-1097	49	96	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-12-1098	35	74	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-12-1098	35	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	6000	No	External Beam	cgy			
TCGA-12-1099	61	101	Treatment	Chemotherapy		Temozolomide	01		mg/m2		Progression				PO		No	75	mg/m2											
TCGA-12-1099	62	104	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/m2		Progression				PO		No	10	mg/m2											
TCGA-12-1099	60	101	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-1597	355	427	Treatment	Chemotherapy		Temozolomide	02	150	mg		Progression				PO		No	1500	mg											
TCGA-12-1597	64	88	Treatment	Chemotherapy		Temozolomide	01	150	mg		Adjuvant				PO		No	1550	mg											
TCGA-12-1597	181	308	Treatment	Chemotherapy		Irinotecan	03	125	mg		Progression				IV		No	2880	mg											
TCGA-12-1597	0	0	Treatment	Chemotherapy		Carmustine	01	8	{wafer}		Adjuvant				INTUM		No	8	{wafer}											
TCGA-12-1597	123	545	Treatment	Chemotherapy		Lomustine	01	110	mg		Adjuvant				PO		No	220	mg											
TCGA-12-1597	313	348	Treatment	Chemotherapy		Temozolomide	05	200	mg		Progression				PO		No	1950	mg											
TCGA-12-1598	160	287	Treatment	Chemotherapy		Temozolomide	03		mg		Adjuvant				PO		No	4500	mg											
TCGA-12-1598	33	82	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	5000	mg											
TCGA-12-1598	33	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		35	6300	No	External Beam	cgy			
TCGA-12-1599	675	727	Treatment	Chemotherapy		Cyclophosphamide	01		mg		Progression				PO		No	5300	mg											
TCGA-12-1599	621	671	Treatment	Chemotherapy		Irinotecan	01		mg		Progression				IV		No	1600	mg											
TCGA-12-1599	621	671	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	1840	mg											
TCGA-12-1599	406	433	Treatment	Targeted Molecular Therapy		Sirolimus			mg		Progression						No	280	mg											
TCGA-12-1599	438	602	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	5520	mg											
TCGA-12-1599	406	433	Treatment	Targeted Molecular Therapy		Erlotinib			mg		Progression						No	14000	mg											
TCGA-12-1599	461	492	Treatment	Chemotherapy		Hydroxyurea	01		mg		Progression				PO		No	30000	mg											
TCGA-12-1599	160	391	Treatment	Chemotherapy		Hydroxyurea	07		mg		Progression				PO		No	66750	mg											
TCGA-12-1599	160	391	Treatment	Targeted Molecular Therapy		Imatinib			mg		Progression						No	90400	mg											
TCGA-12-1599	24	59	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	5880	mg											
TCGA-12-1599	675	727	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	1760	mg											
TCGA-12-1599	96	127	Treatment	Targeted Molecular Therapy		Imatinib			mg		Progression						No	30000	mg											
TCGA-12-1599	438	602	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	5520	mg											
TCGA-12-1599	24	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-1600	43	84	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	5880	mg											
TCGA-12-1600	106	218	Treatment	Chemotherapy		Temozolomide	04		mg		Adjuvant				PO		No	12000	mg											
TCGA-12-1600	43	84	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-1602	17	57	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	6000	mg											
TCGA-12-1602	86	140	Treatment	Chemotherapy		Temozolomide	02		mg		Progression				PO		No	8400	mg											
TCGA-12-1602	17	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-3644	179	486	Treatment	Chemotherapy		Temozolomide	10	200	mg		Adjuvant				PO		No	17000	mg											
TCGA-12-3644	1142	1180	Treatment	Chemotherapy		Temozolomide	1	75	mg		Recurrence				PO		No	3500	mg											
TCGA-12-3644	1583	1611	Treatment	Chemotherapy		Hydroxyurea	1	500	mg		Recurrence				PO		No	14000	mg											
TCGA-12-3644	1583	1611	Treatment	Targeted Molecular Therapy		Sirolimus		5	mg		Recurrence				PO		No	140	mg											
TCGA-12-3644	1639	1722	Treatment	Targeted Molecular Therapy		Chloroquine		500	mg		Recurrence				PO		No	21000	mg											
TCGA-12-3644	1639	1722	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	4200	mg											
TCGA-12-3644	1583	1611	Treatment	Targeted Molecular Therapy		Erlotinib		150	mg		Recurrence				PO		No	4200	mg											
TCGA-12-3644	891	1030	Treatment	Targeted Molecular Therapy		Erlotinib		150	mg		Recurrence				PO		No	21000	mg											
TCGA-12-3644	1611	1639	Treatment	Targeted Molecular Therapy		Sirolimus		5	mg		Recurrence				PO		No	140	mg											
TCGA-12-3644	37	37	Treatment	Chemotherapy		Carmustine	01	8	{wafer}		Adjuvant				INTUM		No	61.6	{wafer}											
TCGA-12-3644	1611	1639	Treatment	Chemotherapy		Hydroxyurea	1	500	mg		Recurrence				PO		No	14000	mg											
TCGA-12-3644	1611	1639	Treatment	Targeted Molecular Therapy		Isotretinoin		80	mg		Recurrence				PO		No	1680	mg											
TCGA-12-3644	1030	1142	Treatment	Chemotherapy		Temozolomide	07	50	mg		Recurrence				PO		No	10080	mg											
TCGA-12-3644	1194	1583	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	18900	mg											
TCGA-12-3644	1611	1639	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	1400	mg											
TCGA-12-3644	1150	1154	Treatment	Targeted Molecular Therapy		6-O-Benzylguanine		30	mg		Recurrence				IV		No	250	mg											
TCGA-12-3644	861	891	Treatment	Chemotherapy		Temozolomide	1	200	mg		Recurrence				PO		No	1700	mg											
TCGA-12-3644	1639	1722	Treatment	Chemotherapy		Irinotecan	3	125	mg		Recurrence				IV		No	1200	mg											
TCGA-12-3644	72	119	Treatment	Chemotherapy		Temozolomide	02	200	mg		Adjuvant				PO		No	3200	mg											
TCGA-12-3644	1611	1639	Treatment	Targeted Molecular Therapy		Erlotinib		150	mg		Recurrence				PO		No	4200	mg											
TCGA-12-3644	1765	1806	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	2100	mg											
TCGA-12-3644	134	179	Treatment	Chemotherapy		Lomustine	1	110	mg		Adjuvant				PO		No	190	mg											
TCGA-12-3644	1194	1583	Treatment	Chemotherapy		Irinotecan	09	125	mg		Recurrence				IV		No	5400	mg											
TCGA-12-3644	1639	1722	Treatment	Chemotherapy		Temozolomide	03	150	mg		Recurrence				PO		No	1825	mg											
TCGA-12-3644	891	1030	Treatment	Targeted Molecular Therapy		Sirolimus		5	mg		Recurrence				PO		No	700	mg											
TCGA-12-3644	1150	1154	Treatment	Targeted Molecular Therapy		6-O-Benzylguanine		120	mg		Recurrence				IV		No	600	mg											
TCGA-12-3644	1583	1611	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	1400	mg											
TCGA-12-3644	1639	1722	Treatment	Targeted Molecular Therapy		Isotretinoin		80	mg		Recurrence				PO		No	1680	mg											
TCGA-12-3644	891	891	Treatment	Radiation Therapy		Radiation 1					Recurrence										Primary Tumor Field		1	1800	No	External Beam	cgy			
TCGA-12-3644	72	119	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		32	5940	No	External Beam	cgy			
TCGA-12-3646	24	66	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	5670	mg											
TCGA-12-3646	248	334	Treatment	Chemotherapy		Irinotecan	02	340	mg		Adjuvant				IV		No	3610.8	mg											
TCGA-12-3646	248	334	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Adjuvant				IV		No	4182	mg											
TCGA-12-3646	1063	1315	Treatment	Chemotherapy		Temozolomide	08	50	mg		Recurrence				PO		No	17920	mg											
TCGA-12-3646	151	234	Treatment	Chemotherapy		Lomustine	02	110	mg		Adjuvant				PO		No	400	mg											
TCGA-12-3646	90	151	Treatment	Chemotherapy		Temozolomide	02	200	mg		Adjuvant				PO		No	3600	mg											
TCGA-12-3646	334	403	Treatment	Chemotherapy		Temozolomide	02	200	mg		Adjuvant				PO		No	3500	mg											
TCGA-12-3646	405	488	Treatment	Chemotherapy		Lomustine	02	110	mg		Adjuvant				PO		No	380	mg											
TCGA-12-3646	24	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-3648	126	452	Treatment	Chemotherapy		Temozolomide	11	100	mg		Adjuvant				PO		No	46200	mg											
TCGA-12-3648	738	784	Treatment	Chemotherapy		Etoposide	01	50	mg		Recurrence				PO		No	1575	mg											
TCGA-12-3648	83	452	Treatment	Immunotherapy		Pep-3-Klh		500	ug		Adjuvant				PO		No	6500	ug											
TCGA-12-3648	738	784	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	1400	mg											
TCGA-12-3648	508	731	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	10950	mg											
TCGA-12-3648	14	67	Treatment	Chemotherapy		Temozolomide	1	75	mg		Adjuvant				PO		No	5880	mg											
TCGA-12-3648	508	731	Treatment	Chemotherapy		Irinotecan	05	125	mg		Recurrence				IV		No	3450	mg											
TCGA-12-3648	738	784	Treatment	Chemotherapy		Temozolomide	1	50	mg		Recurrence				PO		No	2800	mg											
TCGA-12-3648	14	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	6000	No	External Beam	cgy			
TCGA-12-3649	240	350	Treatment	Immunotherapy		Attac					Adjuvant				OTHER		No													
TCGA-12-3649	186	245	Treatment	Immunotherapy		Attac					Adjuvant				OTHER		No													
TCGA-12-3649	186	240	Treatment	Chemotherapy		Temozolomide	01	200	mg		Adjuvant				PO		No	2000	mg											
TCGA-12-3649	186	240	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg/kg		Adjuvant				IV		No		mg/kg											
TCGA-12-3649	240	350	Treatment	Chemotherapy		Temozolomide	03	200	mg		Adjuvant				PO		No	6000	mg											
TCGA-12-3649	240	347	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg/kg		Adjuvant				IV		No		mg/kg											
TCGA-12-3650	239	307	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	3860	mg											
TCGA-12-3650	91	148	Treatment	Chemotherapy		Temozolomide	02	200	mg		Adjuvant				PO		No	2000	mg											
TCGA-12-3650	239	307	Treatment	Targeted Molecular Therapy		Erlotinib		200	mg		Recurrence				PO		No	11200	mg											
TCGA-12-3650	91	148	Treatment	Chemotherapy		Irinotecan	02	340	mg		Adjuvant				IV		No	6120	mg											
TCGA-12-3650	26	72	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	6930	mg											
TCGA-12-3650	307	333	Treatment	Chemotherapy		Etoposide	01	50	mg		Progression				PO		No	2100	mg											
TCGA-12-3650	26	72	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Adjuvant				IV		No	3003	mg											
TCGA-12-3650	91	148	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Adjuvant				IV		No	3892	mg											
TCGA-12-3650	152	239	Treatment	Chemotherapy		Irinotecan	03	125	mg		Adjuvant				IV		No	1620	mg											
TCGA-12-3650	148	239	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Adjuvant				IV		No	5838	mg											
TCGA-12-3650	307	333	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		No	1894	mg											
TCGA-12-3650	152	239	Treatment	Chemotherapy		Temozolomide	03	200	mg		Progression				PO		No	3000	mg											
TCGA-12-3650	26	72	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-12-3651	221	358	Treatment	Targeted Molecular Therapy		Bevacizumab		5	mg		Adjuvant				IV		No	2840	mg											
TCGA-12-3651	186	212	Treatment	Chemotherapy		Temozolomide	01	150	mg		Adjuvant				PO		No	1400	mg											
TCGA-12-3651	43	85	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Adjuvant				IV		No	2430	mg											
TCGA-12-3651	43	85	Treatment	Chemotherapy		Temozolomide	1	75	mg		Adjuvant				PO		No	5880	mg											
TCGA-12-3651	221	358	Treatment	Chemotherapy		Irinotecan	04	40	mg		Adjuvant				IV		No	592	mg											
TCGA-12-3651	221	358	Treatment	Chemotherapy		Temozolomide	04	150	mg		Adjuvant				PO		No	5600	mg											
TCGA-12-3651	43	85	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		32	6000	No	External Beam	cgy			
TCGA-12-3652	750	792	Treatment	Targeted Molecular Therapy		Imatinib		300	mg		Recurrence				PO		No	8400	mg											
TCGA-12-3652	585	750	Treatment	Targeted Molecular Therapy		Imatinib		400	mg		Recurrence				PO		No	56000	mg											
TCGA-12-3652	291	358	Treatment	Chemotherapy		Etoposide	1	50	mg		Recurrence				PO		No	1575	mg											
TCGA-12-3652	750	792	Treatment	Targeted Molecular Therapy		Hydroxyurea		500	mg		Recurrence				PO		No	2800	mg											
TCGA-12-3652	91	133	Treatment	Chemotherapy		Lomustine	01	110	mg		Adjuvant				PO		No	220	mg											
TCGA-12-3652	228	288	Treatment	Chemotherapy		Temozolomide	02	200	mg		Recurrence				PO		No	4000	mg											
TCGA-12-3652	585	750	Treatment	Targeted Molecular Therapy		Hydroxyurea		500	mg		Recurrence				PO		No	14000	mg											
TCGA-12-3652	21	67	Treatment	Chemotherapy		Temozolomide	02	150	mg		Adjuvant				PO		No	3000	mg											
TCGA-12-3652	161	203	Treatment	Chemotherapy		Lomustine	01	82.5	mg		Adjuvant				PO		No	160	mg											
TCGA-12-3652	469	571	Treatment	Chemotherapy		Etoposide	4	50	mg		Recurrence				PO		No	8400	mg											
TCGA-12-3652	21	60	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		29	5800	No	External Beam	cgy			
TCGA-12-3653	46	87	Treatment	Chemotherapy		Temozolomide	1	75	mg		Adjuvant				PO		No	6300	mg											
TCGA-12-3653	128	224	Treatment	Chemotherapy		Temozolomide	03	150	mg		Adjuvant				PO		No	4500	mg											
TCGA-12-3653	316	371	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Progression				IV		No	4000	mg											
TCGA-12-3653	128	224	Treatment	Immunotherapy		Daclizumab		1	mg		Adjuvant				OTHER		No	406.4	mg											
TCGA-12-3653	287	315	Treatment	Targeted Molecular Therapy		Pegdinetanib		2	mg		Adjuvant				IV		No	199	mg											
TCGA-12-3653	316	371	Treatment	Chemotherapy		Etoposide	02	50	mg		Progression				PO		No	4200	mg											
TCGA-12-3653	46	87	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		32	6000	No	External Beam	cgy			
TCGA-12-5295	29	71	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	4725	mg											
TCGA-12-5295	88	277	Treatment	Chemotherapy		Irinotecan	03	340	mg		Adjuvant				IV		No	4590	mg											
TCGA-12-5295	88	277	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Adjuvant				IV		No	4950	mg											
TCGA-12-5295	277	323	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Adjuvant				IV		No	1650	mg											
TCGA-12-5295	29	71	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-12-5299	45	80	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	5250	mg											
TCGA-12-5299	45	73	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Adjuvant				IV		No	3000	mg											
TCGA-12-5299	45	77	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		21	3780	No	External Beam	cgy			
TCGA-12-5301	24	59	Treatment	Chemotherapy		Temozolomide	01	75	mg		Adjuvant				PO		No	5400	mg											
TCGA-12-5301	24	59	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		26	4680	No	External Beam	cgy			
TCGA-14-0736	207		Treatment	Chemotherapy		Carmustine			{wafer}		Progression				OTHER		No	8	{wafer}											
TCGA-14-0736	0		Treatment	Hormone Therapy		Dexamethasone					Progression				PO		No													
TCGA-14-0736	128		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-0736	371	376	Treatment	Chemotherapy		Temozolomide	01		mg		Progression				PO		No	2000	mg											
TCGA-14-0736	58	102	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-14-0740	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No		mg											
TCGA-14-0781	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant				PO		No		mg											
TCGA-14-0783	-1		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-0783	32	147	Treatment	Chemotherapy		Carboxyamidotriazole			mg		Adjuvant				PO		No	108450	mg											
TCGA-14-0783	32	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-0786	140	142	Treatment	Chemotherapy		Cisplatin	01				Adjuvant				IV		No													
TCGA-14-0786	574	651	Treatment	Chemotherapy		Tetrathiomolybdate			mg		Adjuvant				PO		No	300	mg											
TCGA-14-0786	567	570	Treatment	Chemotherapy		Tioguanine	01		mg		Adjuvant				IV		No	1200	mg											
TCGA-14-0786	140	142	Treatment	Chemotherapy		Carmustine	01				Adjuvant				IV		No													
TCGA-14-0786	182	210	Treatment	Chemotherapy		Irinotecan	03		mg		Adjuvant				IV		No	1124	mg											
TCGA-14-0786	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-0786	526	567	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	150	mg											
TCGA-14-0786	127		Treatment	Hormone Therapy		Dexamethasone					Adjuvant																			
TCGA-14-0786	567	570	Treatment	Chemotherapy		Carmustine	01		mg		Adjuvant				IV		No	69	mg											
TCGA-14-0786	659		Treatment	Chemotherapy		Carboplatin					Adjuvant				IV															
TCGA-14-0786	659		Treatment	Chemotherapy		Etoposide					Adjuvant				IV															
TCGA-14-0786	567	570	Treatment	Chemotherapy		Streptozocin	01		mg		Adjuvant				IV		No	3400	mg											
TCGA-14-0786	308	357	Treatment	Chemotherapy		Procarbazine	02		mg		Adjuvant				PO		No	12600	mg											
TCGA-14-0786	56	101	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-14-0787	15	41	Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant							720	mg											
TCGA-14-0789	44	75	Treatment	Chemotherapy		Temozolomide	1		mg/day		Adjuvant				PO			120	mg/day											
TCGA-14-0789	118		Treatment	Chemotherapy		Carmustine	1		{wafer}		Progression				OTHER		No	8	{wafer}											
TCGA-14-0789	0	118	Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant				PO		No	2000	mg											
TCGA-14-0789	119	224	Treatment	Hormone Therapy		Dexamethasone			mg		Progression				PO		No	1680	mg											
TCGA-14-0789	44	80	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		26	5280		External Beam	cgy			
TCGA-14-0790	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No		mg											
TCGA-14-0790	0		Treatment	Chemotherapy		Carmustine			{wafer}		Adjuvant				OTHER		No	8	{wafer}											
TCGA-14-0790	15	410	Treatment	Chemotherapy		Temozolomide	09		mg		Adjuvant				PO		No	17700	mg											
TCGA-14-0790	28	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-0812	0		Treatment	Chemotherapy		Carmustine			{wafer}		Adjuvant				OTHER		No	8	{wafer}											
TCGA-14-0812	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-0813	0	41	Treatment	Hormone Therapy		Dexamethasone			mg/day		Adjuvant						No	16	mg/day											
TCGA-14-0817	0	15	Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No	176	mg											
TCGA-14-0862	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No		mg											
TCGA-14-0865	46	167	Treatment	Chemotherapy		Temozolomide	04		mg		Adjuvant				PO		No	9500	mg											
TCGA-14-0865	205		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-0865	0		Treatment	Hormone Therapy		Dexamethasone					Other, Specify In Notes						No													
TCGA-14-0865	46	77	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-0865	293	293	Treatment	Radiation Therapy		Radiation 2					Progression										Distant Recurrence			1500	No	External Beam	cgy			
TCGA-14-0866	0		Treatment	Hormone Therapy		Dexamethasone					Other, Specify In Notes																			
TCGA-14-0866	21	325	Treatment	Chemotherapy		Temozolomide	07		mg		Other, Specify In Notes				PO		No	62415	mg											
TCGA-14-0866	31	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-0867	0	15	Treatment	Hormone Therapy		Dexamethasone			mg/day		Adjuvant						No	24	mg/day											
TCGA-14-0871	0	281	Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No	288	mg											
TCGA-14-0871	22	72	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-14-1034	282		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1034	448		Treatment	Chemotherapy		Carmustine			{wafer}		Progression				OTHER		No	8	{wafer}											
TCGA-14-1034	8		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1034	54	78	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	5400	No	External Beam	cgy			
TCGA-14-1037	439	538	Treatment	Chemotherapy		Temozolomide	04		mg		Progression				PO		No	6000	mg											
TCGA-14-1037	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1037	25	95	Treatment	Chemotherapy		Oxaliplatin	06		mg		Adjuvant				IV		No		mg											
TCGA-14-1037	326		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1037	346	433	Treatment	Targeted Molecular Therapy		Bortezomib			mg		Progression				IV		No	36.8	mg											
TCGA-14-1037	118	165	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1043	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No		mg											
TCGA-14-1043	19	22	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		4	800	No	External Beam	cgy			
TCGA-14-1395	14	28	Treatment	Chemotherapy		Oxaliplatin	02		mg		Adjuvant				IV		No	679	mg											
TCGA-14-1395	0	41	Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1402	344	529	Treatment	Chemotherapy		Temozolomide	06		mg		Progression				PO		No	9500	mg											
TCGA-14-1402	316		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1402	333		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1402	316		Treatment	Hormone Therapy		Prednisone					Adjuvant				PO		No													
TCGA-14-1402	57	66	Treatment	Chemotherapy		Arsenic Trioxide	06		mg		Adjuvant				IV		No	63	mg											
TCGA-14-1402	659	832	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression				PO		No	11000	mg											
TCGA-14-1402	659	832	Treatment	Chemotherapy		Carboplatin	06		mg		Progression				IV		No	4969	mg											
TCGA-14-1402	619	633	Treatment	Targeted Molecular Therapy		Sorafenib			mg		Progression				PO		No	14000	mg											
TCGA-14-1402	28	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1450	127	961	Treatment	Chemotherapy		Temozolomide	15		mg		Progression				PO		No	19450	mg											
TCGA-14-1450	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No		mg											
TCGA-14-1450	22	65	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	5160	mg											
TCGA-14-1450	826		Treatment	Hormone Therapy		Dexamethasone			mg		Progression						No		mg											
TCGA-14-1450	1024	1233	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	7800	mg											
TCGA-14-1450	22	65	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1451	411	480	Treatment	Chemotherapy		Etoposide	04		mg		Progression				IV		No	780	mg											
TCGA-14-1451	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1451	382	504	Treatment	Targeted Molecular Therapy		Erlotinib			mg		Progression						No	9000	mg											
TCGA-14-1451	153		Treatment	Chemotherapy		Carmustine			{wafer}		Progression				OTHER		No	8	{wafer}											
TCGA-14-1451	411	480	Treatment	Chemotherapy		Cisplatin	04		mg		Progression				IV		No	780	mg											
TCGA-14-1451	501	566	Treatment	Chemotherapy		Carmustine	02		mg		Progression				IV		No	720	mg											
TCGA-14-1451	59	101	Treatment	Chemotherapy		Temozolomide	01		mg		Progression				PO		No	5880	mg											
TCGA-14-1451	411	480	Treatment	Chemotherapy		Vincristine	04		mg		Progression				IV		No	8	mg											
TCGA-14-1451	19		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1451	20	34	Treatment	Chemotherapy		Oxaliplatin	02		mg		Progression				IV		No	641	mg											
TCGA-14-1451	60	101	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1452	26	185	Treatment	Chemotherapy		Temozolomide	03		mg		Other, Specify In Notes				PO		No	9,880	mg											
TCGA-14-1452	172	216	Treatment	Hormone Therapy		Dexamethasone					Other, Specify In Notes						No													
TCGA-14-1452	0		Treatment	Chemotherapy		Carmustine			{wafer}		Adjuvant				OTHER		No	8	{wafer}											
TCGA-14-1452	26	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1454	0		Treatment	Chemotherapy		Carmustine			{wafer}		Adjuvant				OTHER		No	8	{wafer}											
TCGA-14-1454	291		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1454	29	235	Treatment	Chemotherapy		Temozolomide	7		mg		Adjuvant				PO		No	15370	mg											
TCGA-14-1454	309	900	Treatment	Chemotherapy		Hydroxyurea	18		mg		Progression				PO		No	590,000	mg											
TCGA-14-1454	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1454	309	900	Treatment	Chemotherapy		Imatinib	18		mg		Progression				PO		No	236,000	mg											
TCGA-14-1454	29	78	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1455	17		Treatment	Chemotherapy		Carmustine			{wafer}		Adjuvant				OTHER		No	8	{wafer}											
TCGA-14-1455	17	28	Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1456	98		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1456	102	549	Treatment	Targeted Molecular Therapy		Erlotinib					Progression				PO		No													
TCGA-14-1456	25	70	Treatment	Chemotherapy		Arsenic Trioxide	13		mg		Adjuvant				PO		No	290.94	mg											
TCGA-14-1456	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1456	1129	1246	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						Yes	3344	mg											
TCGA-14-1456	102	1128	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression				PO		No	11704	mg											
TCGA-14-1456	28	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1458	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1458	83	146	Treatment	Chemotherapy		Temozolomide	03		mg		Progression				PO		No	6450	mg											
TCGA-14-1458	81		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1458	19	61	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	8400	mg											
TCGA-14-1458	89	162	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression				IV		No	10400	mg											
TCGA-14-1458	20	61	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1459	22		Treatment	Chemotherapy		Temozolomide	05		mg		Adjuvant				PO		No	9000	mg											
TCGA-14-1459	22	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1794	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1794	28	28	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		1	1800	No	External Beam	cgy			
TCGA-14-1795	0		Treatment	Chemotherapy		Carmustine			{wafer}		Adjuvant				OTHER		No	8	{wafer}											
TCGA-14-1795	0	60	Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1821	331		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1821	40	69	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	5400	mg											
TCGA-14-1821	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1821	27	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1823	20	450	Treatment	Chemotherapy		Temozolomide	12		mg		Adjuvant				PO		No	11150	mg											
TCGA-14-1823	378	478	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Progression						No	6400	mg											
TCGA-14-1823	20	450	Treatment	Chemotherapy		Temozolomide	12				Progression				PO		No													
TCGA-14-1823	0		Treatment	Chemotherapy		Carmustine			{wafer}		Adjuvant				OTHER		No	8	{wafer}											
TCGA-14-1823	140		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1823	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1823	29	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1825	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1825	82		Treatment	Hormone Therapy		Dexamethasone					Progression						No													
TCGA-14-1825	21	79	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-1827	42	46	Treatment	Chemotherapy		Cisplatin	01				Adjuvant				IV		No													
TCGA-14-1827	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1827	42	46	Treatment	Chemotherapy		Carmustine	01				Adjuvant				IV		No													
TCGA-14-1829	0		Treatment	Hormone Therapy		Dexamethasone					Adjuvant						No													
TCGA-14-1829	8		Treatment	Chemotherapy		Temozolomide	04		mg		Adjuvant				PO		Yes	10040	mg											
TCGA-14-1829	8	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-2554	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No		mg											
TCGA-14-2554	43	43	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			80	No	Radioisotope	mci			
TCGA-14-2555	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No		mg											
TCGA-14-2555	34	242	Treatment	Chemotherapy		Temozolomide	04		mg		Adjuvant				PO		No	12600	mg											
TCGA-14-2555	34	78	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-3476	0	20	Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant				IV		No		mg											
TCGA-14-3477	0		Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant								mg											
TCGA-14-3477	35	67	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	4480	mg											
TCGA-14-3477	56	70	Treatment	Targeted Molecular Therapy		Bevacizumab			mg		Adjuvant						No	1480	mg											
TCGA-14-3477	35	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-14-4157	19	67	Treatment	Chemotherapy		Temozolomide		75	mg		Adjuvant				PO		No	3600	mg											
TCGA-14-4157	96		Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		Yes	355	mg											
TCGA-14-4157	19	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-15-0742	28	59	Treatment	Chemotherapy		Temozolomide			mg/m2/day		Adjuvant				PO		No	75	mg/m2/day											
TCGA-15-0742	259	300	Treatment	Targeted Molecular Therapy		Vorinostat			mg		Adjuvant						No	200	mg											
TCGA-15-1444	38	72	Treatment	Chemotherapy		Carmustine											No			Yes										
TCGA-15-1444	38	72	Treatment	Chemotherapy		Irinotecan											No			Yes										
TCGA-15-1444	6	78	Treatment	Radiation Therapy		Radiation 1							complete response								Primary Tumor Field		30	6000	No	External	cgy			
TCGA-15-1446	68	280	Treatment	Chemotherapy		Temozolomide	6				Adjuvant				PO		No													
TCGA-15-1446	68	98	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-15-1447	9	130	Treatment	Chemotherapy		Irinotecan	2				Adjuvant						No													
TCGA-15-1447	9	130	Treatment	Chemotherapy		Temozolomide	2				Adjuvant						No													
TCGA-15-1447	9	130	Treatment	Chemotherapy		Carmustine	2				Adjuvant						No													
TCGA-15-1447	9	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-15-1449	32	74	Treatment	Chemotherapy		Temozolomide					Adjuvant				PO		No													
TCGA-15-1449	32	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-16-0848	30	71	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	7000	No	External Beam	cgy			
TCGA-16-0849	29	71	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	5400	No	External Beam	cgy			
TCGA-16-0850	20	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6020	No	External Beam	cgy			
TCGA-16-0850	476	489	Treatment	Radiation Therapy		Radiation 2					Other, Specify In Notes	T Spine											10	1200	No	External Beam	cgy			
TCGA-16-0861	27	47	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		15	4000	No	External Beam	cgy			
TCGA-16-1045	53	64	Treatment	Radiation Therapy		Radiation 1					Other, Specify In Notes	Boos									Primary Tumor Field		6	1200	No	External Beam	cgy			
TCGA-16-1045	22	54	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		23	4600	No	External Beam	cgy			
TCGA-16-1055	47	83	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-16-1056	20	62	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-16-1060	28	41	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		10	3000	No	External Beam	cgy			
TCGA-16-1062	34	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-16-1063	53	73	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		15	4005	No	External Beam	cgy			
TCGA-19-0955	31	277	Treatment	Chemotherapy		Temozolomide	6		mg		Adjuvant				PO		No	360	mg											
TCGA-19-0955	79	79	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		7	140	No	External Beam	cgy			
TCGA-19-0955	31	70	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		23	460	No	External Beam	cgy			
TCGA-19-0957	566	580	Treatment	Chemotherapy		Bevacizumab	02		mg		Progression				IV		No	1660	mg											
TCGA-19-0957	594	608	Treatment	Chemotherapy		Bevacizumab	02		mg		Progression				IV		No	1660	mg											
TCGA-19-0957	538	552	Treatment	Chemotherapy		Irinotecan	02		mg		Progression				IV		No	470	mg											
TCGA-19-0957	594	608	Treatment	Chemotherapy		Irinotecan	02		mg		Progression				IV		No	470	mg											
TCGA-19-0957	120	273	Treatment	Chemotherapy		Temozolomide	06		mg		Adjuvant				PO		No	9000	mg											
TCGA-19-0957	368	372	Treatment	Chemotherapy		Temozolomide	01		mg		Recurrence				PO		No	1500	mg											
TCGA-19-0957	35	81	Treatment	Chemotherapy		Temozolomide	06		mg		Other, Specify In Notes				PO		No	5880	mg											
TCGA-19-0957	538	552	Treatment	Chemotherapy		Bevacizumab	02		mg		Progression				IV		No	1660	mg											
TCGA-19-0957	35	81	Treatment	Radiation Therapy		Radiation 1					Other, Specify In Notes	Concurrent									Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-0960	42		Treatment	Chemotherapy		Temozolomide	5		mg		Adjuvant				PO			300	mg											
TCGA-19-0960	42	73	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	600	No	External Beam	cgy			
TCGA-19-0963	129	270	Treatment	Chemotherapy		Temozolomide	5	260	mg		Adjuvant				PO		No	6500	mg											
TCGA-19-0963	34	84	Treatment	Chemotherapy		Temozolomide	1	120	mg		Adjuvant				PO		No	5160	mg											
TCGA-19-0963	34	84	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		34	6100	No	External Beam	cgy			
TCGA-19-0964	39	82	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		No	140	mg											
TCGA-19-0964	39	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	600	No	External Beam	cgy			
TCGA-19-1385	16	57	Treatment	Chemotherapy		Temozolomide	06		mg		Other, Specify In Notes				PO		No	6300	mg											
TCGA-19-1385	89	93	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	1600	mg											
TCGA-19-1385	16	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-1386	21	62	Treatment	Chemotherapy		Temozolomide	4		mg		Adjuvant				PO		No	5880	mg											
TCGA-19-1386	216	229	Treatment	Chemotherapy		Erlotinib	01		mg		Adjuvant				PO		No	1800	mg											
TCGA-19-1386	230	236	Treatment	Chemotherapy		Erlotinib	01		mg		Adjuvant				PO		No	1050	mg											
TCGA-19-1386	142	234	Treatment	Chemotherapy		Temozolomide	04		mg		Adjuvant				PO		No	6000	mg											
TCGA-19-1386	89	93	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	1500	mg											
TCGA-19-1386	21	62	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-1387	19	58	Treatment	Chemotherapy		Temozolomide	01		mg		Other, Specify In Notes				PO		No	5600	mg											
TCGA-19-1387	19	58	Treatment	Radiation Therapy		Radiation 1					Other, Specify In Notes	Concurrent									Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-1388	269	328	Treatment	Chemotherapy		Temozolomide	01		mg		Progression				PO		No	6000	mg											
TCGA-19-1388	363	377	Treatment	Chemotherapy		Bevacizumab	02		mg		Progression				IV		No	1750	mg											
TCGA-19-1388	97	250	Treatment	Chemotherapy		Temozolomide	06		mg		Other, Specify In Notes				PO		No	9000	mg											
TCGA-19-1388	21	63	Treatment	Chemotherapy		Temozolomide	01		mg		Other, Specify In Notes				PO		No	6020	mg											
TCGA-19-1388	21	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-1389	10	20	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	1980	mg											
TCGA-19-1389	48	67	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	3600	mg											
TCGA-19-1389	26	41	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	2880	mg											
TCGA-19-1389	26	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-1786	45	92	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-1787	112	264	Treatment	Chemotherapy		Temozolomide	06	280	mg		Adjuvant				PO		No	9200	mg											
TCGA-19-1787	42	85	Treatment	Chemotherapy		Temozolomide	1	140	mg		Adjuvant				PO		No	5880	mg											
TCGA-19-1787	312	347	Treatment	Chemotherapy		Bevacizumab	03	10	mg		Recurrence				IV		No	900	mg											
TCGA-19-1787	42	85	Treatment	Chemotherapy		Temozolomide	01	140	mg		Adjuvant				PO		No	5880	mg											
TCGA-19-1787	42	85	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-1789	26	32	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	980	mg											
TCGA-19-1789	26	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-1790	25	66	Treatment	Chemotherapy		Temozolomide	1	140	mg		Adjuvant				PO		No	5880	mg											
TCGA-19-1790	25	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-2619	57	85	Treatment	Chemotherapy		Temozolomide	1	125	mg		Adjuvant				PO		No	3625	mg											
TCGA-19-2619	113	117	Treatment	Chemotherapy		Temozolomide	1	250	mg		Adjuvant				PO		No	1250	mg											
TCGA-19-2619	153	295	Treatment	Chemotherapy		Bevacizumab	10	630	mg		Progression				IV		No	630	mg											
TCGA-19-2619	37	85	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		25	4500	No	External Beam	cgy			
TCGA-19-2619	37	85	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		8	1440	No	External Beam	cgy			
TCGA-19-2620	33	51	Treatment	Chemotherapy		Temozolomide	1				Adjuvant				PO		No													
TCGA-19-2620	33	51	Treatment	Radiation Therapy		Radiation 1					Adjuvant	Patient Did Not Recieve Treatment At Site, Unable To Obtain All Radiation Details									Primary Tumor Field				No	External Beam				
TCGA-19-2623	25	53	Treatment	Chemotherapy		Temozolomide	1	140	mg		Adjuvant				PO		No	4060	mg											
TCGA-19-2623	105		Treatment	Chemotherapy		Temozolomide	5	240	mg		Adjuvant				PO		Yes	1200	mg											
TCGA-19-2623	110	114	Treatment	Chemotherapy		Temozolomide	1	280	mg		Adjuvant				PO		No	1400	mg											
TCGA-19-2623	25	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-2629	148	198	Treatment	Chemotherapy		Bevacizumab	4				Progression				IV		No													
TCGA-19-2629	104	135	Treatment	Chemotherapy		Temozolomide	2	350	mg		Adjuvant				PO		No	3500	mg											
TCGA-19-2629	10	69	Treatment	Chemotherapy		Temozolomide	1	180	mg		Adjuvant				PO		No	7560	mg											
TCGA-19-2629	10	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-2631	42	88	Treatment	Radiation Therapy		Radiation 1					Adjuvant	Fu Interval -Monthly									Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-4065	78	89	Treatment	Chemotherapy		Temozolomide	1	180	mg		Recurrence				PO		No	2160	mg											
TCGA-19-4065	39	70	Treatment	Chemotherapy		Temozolomide	1	180	mg		Adjuvant				PO		No	5400	mg											
TCGA-19-4065	166	170	Treatment	Chemotherapy		Temozolomide	1	480	mg		Recurrence				PO		No	2400	mg											
TCGA-19-4065	123	128	Treatment	Chemotherapy		Temozolomide	1	360	mg		Recurrence				PO		No	1800	mg											
TCGA-19-4065	39	89	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-4068	60	75	Treatment	Chemotherapy		Temozolomide	1	105	mg		Adjuvant				PO		No	1200	mg											
TCGA-19-4068	83	109	Treatment	Chemotherapy		Temozolomide	1	105	mg		Adjuvant				PO		No	2835	mg											
TCGA-19-4068	60	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-19-4068	80	109	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-19-5947	34	42	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		7	1750	No	External Beam	cgy			
TCGA-19-5950	27	70	Treatment	Chemotherapy		Temozolomide		140	mg		Adjuvant				PO		No	6020	mg											
TCGA-19-5950	134	249	Treatment	Chemotherapy		Temozolomide	5	350	mg		Adjuvant				PO		No	8750	mg											
TCGA-19-5950	106	110	Treatment	Chemotherapy		Temozolomide	1	270	mg		Adjuvant				PO		No	1350	mg											
TCGA-19-5950	287	343	Treatment	Chemotherapy		Vismodegib							clinical progressive disease				No			Yes										
TCGA-19-5950	37	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-5951	50	94	Treatment	Chemotherapy		Temozolomide		165	mg		Adjuvant				PO		No	6270	mg											
TCGA-19-5951	50	94	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-5952	71	107	Treatment	Radiation Therapy		Radiation 1					Adjuvant														No	External Beam				
TCGA-19-5954	32	75	Treatment	Chemotherapy		Temozolomide		135	mg		Adjuvant				PO		No	5805	mg											
TCGA-19-5954	103	107	Treatment	Chemotherapy		Temozolomide	1	270	mg		Adjuvant				PO		No	1350	mg											
TCGA-19-5954	32	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-5956	51	70	Treatment	Chemotherapy		Temozolomide					Adjuvant				PO		No													
TCGA-19-5956	51	70	Treatment	Chemotherapy		Bevacizumab							stable disease				No			Yes										
TCGA-19-5956	202	604	Treatment	Chemotherapy		Temozolomide							stable disease				No			No										
TCGA-19-5956	51	94	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		31	6000	No	External Beam	cgy			
TCGA-19-5958	111	248	Treatment	Chemotherapy		Temozolomide	6	300-400	mg	2	Adjuvant				PO		No	11500	mg											
TCGA-19-5958	56	265	Treatment	Chemotherapy		Bevacizumab	15	745-835	mg	3	Adjuvant				IV		Yes													
TCGA-19-5958	34	80	Treatment	Chemotherapy	Daily for 42 Days	Temozolomide		145	mg	1	Adjuvant				PO		No	6090	mg											
TCGA-19-5958	34	80	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-19-5959	73	88	Treatment	Chemotherapy		Temozolomide		125	mg		Adjuvant				PO		No	2125	mg											
TCGA-19-5959	131	290	Treatment	Chemotherapy		Temozolomide							clinical progressive disease				No			No										
TCGA-19-5959	360	388	Treatment	Chemotherapy		Bevacizumab							clinical progressive disease				No			No										
TCGA-19-5959	39	89	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-5960	30	71	Treatment	Chemotherapy		Temozolomide		135	mg		Adjuvant				PO		No	5670	mg											
TCGA-19-5960	55	165	Treatment	Chemotherapy		Bevacizumab							stable disease				No			Yes										
TCGA-19-5960	123	155	Treatment	Chemotherapy		Temozolomide							stable disease				No			No										
TCGA-19-5960	30	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-19-A60I	72	114	Treatment	Chemotherapy		Temozolomide							stable disease				No			No										
TCGA-19-A60I	154		Treatment	Chemotherapy		Temozolomide											Yes			No										
TCGA-19-A60I	72	114	Treatment	Radiation Therapy		Radiation 1							stable disease								Primary Tumor Field		29	5945	No	External	cgy			
TCGA-19-A6J5	34	76	Treatment	Chemotherapy		Temozolomide							stable disease				No			No										
TCGA-19-A6J5	111	658	Treatment	Chemotherapy		Temozolomide							stable disease				No			No										
TCGA-19-A6J5	812		Treatment	Chemotherapy		Bevacizumab											Yes			No										
TCGA-19-A6J5	847		Treatment	Chemotherapy		Lomustine											Yes			No										
TCGA-19-A6J5	34	76	Treatment	Radiation Therapy		Radiation 1							stable disease								Primary Tumor Field		30	6000	No	External	cgy			
TCGA-26-1438	31	73	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		No	5670	mg											
TCGA-26-1438	104	206	Treatment	Chemotherapy		Temozolomide	4		mg		Adjuvant				PO		No	1440	mg											
TCGA-26-1438	221	221	Treatment	Chemotherapy		Lomustine	1		mg		Progression				PO		No	210	mg											
TCGA-26-1438	221	264	Treatment	Targeted Molecular Therapy		Cediranib			mg		Progression						No	880	mg											
TCGA-26-1438	31	73	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-26-1439	31	81	Treatment	Chemotherapy		Temozolomide					Adjuvant				PO		No													
TCGA-26-1439	31	81	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		34	6120	No	External Beam	cgy			
TCGA-26-1440	30	78	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	6300	mg											
TCGA-26-1440	108		Treatment	Chemotherapy		Temozolomide	08		mg		Adjuvant				PO		No	3140	mg											
TCGA-26-1440	30	78	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		34	6120	No	External Beam	cgy			
TCGA-26-1442	27	66	Treatment	Chemotherapy		Motexafin Gadolinium	22	340	mg		Adjuvant				IV		No	7480	mg											
TCGA-26-1442	94	872	Treatment	Chemotherapy		Temozolomide	27	200	mg/m2		Adjuvant				PO		No	27000	mg/m2											
TCGA-26-1442	27	66	Treatment	Chemotherapy		Temozolomide	01	140	mg		Adjuvant				PO		No	5600	mg											
TCGA-26-1442	27	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-26-1443	32	79	Treatment	Chemotherapy		Temozolomide	1		mg		Adjuvant				PO		No	5460	mg											
TCGA-26-1443	111	195	Treatment	Chemotherapy		Temozolomide	3		mg		Adjuvant				PO		No	915	mg											
TCGA-26-1443	26	79	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-26-1799	101	148	Treatment	Chemotherapy		Temozolomide	02		mg		Adjuvant				PO		No	4150	mg											
TCGA-26-1799	31	73	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-26-5132	40	83	Treatment	Chemotherapy		Temozolomide	1	110	mg		Adjuvant				PO		No	4620	mg											
TCGA-26-5132	205	205	Treatment	Chemotherapy		Temozolomide	1	150	mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-26-5132	40	83	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-26-5133	25	68	Treatment	Chemotherapy		Temozolomide	1	75	mg/m2		Adjuvant				PO		No	3300	mg/m2											
TCGA-26-5133	116	120	Treatment	Chemotherapy		Temozolomide	1	150	mg/m2		Adjuvant				PO		No	750	mg/m2											
TCGA-26-5133	144	351	Treatment	Chemotherapy		Temozolomide	8	200	mg/m2		Adjuvant				PO		No	8000	mg/m2											
TCGA-26-5133	25	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-26-5134	60	103	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-26-6173	129	245	Treatment	Chemotherapy		Temozolomide	05	200	mg/m2		Adjuvant				PO		No	1000	mg/m2											
TCGA-26-6173	24		Treatment	Chemotherapy		Cilengitide	30	4000	mg		Adjuvant				IV		Yes	120000	mg											
TCGA-26-6173	101	105	Treatment	Chemotherapy		Temozolomide	01	150	mg/m2		Adjuvant				PO		No	750	mg/m2											
TCGA-26-6173	31	70	Treatment	Chemotherapy		Temozolomide	75	75	mg/m2		Adjuvant				PO		No	2250	mg/m2											
TCGA-26-6173	31	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-26-6174	29	66	Treatment	Chemotherapy		Temozolomide	06	75	mg/m2		Adjuvant				PO		No	2850	mg/m2											
TCGA-26-6174	29	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-26-A7UX	35	235	Treatment	Chemotherapy		Temozolomide											No			No										
TCGA-26-A7UX	511		Treatment	Chemotherapy		Lomustine							stable disease				Yes			No										
TCGA-26-A7UX	511		Treatment	Targeted Molecular Therapy		Bevacizumab							stable disease				Yes			No										
TCGA-26-A7UX	23	65	Treatment	Radiation Therapy		Radiation 1															Primary Tumor Field		30	60	No	External	gy			
TCGA-27-1830	8	86	Treatment	Chemotherapy		Temozolomide	03		mg		Adjuvant				OTHER		No	3750	mg											
TCGA-27-1830	-1	70	Treatment	Hormone Therapy		Dexamethasone			mg/day		Adjuvant						No	4	mg/day											
TCGA-27-1830	8	86	Treatment	Chemotherapy		Cisplatin	03		mg		Adjuvant				OTHER		No	420	mg											
TCGA-27-1830	18	22	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-27-1830	46	50	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-27-1831	-8	505	Treatment	Hormone Therapy		Dexamethasone		8	mg		Adjuvant				OTHER		No	4104	mg											
TCGA-27-1831	-8	505	Treatment	Hormone Therapy		Oxcarbazepine		600	mg		Adjuvant				PO		No	307800	mg											
TCGA-27-1831	6	103	Treatment	Chemotherapy		Temozolomide	03	200	mg		Adjuvant				PO		No	3400	mg											
TCGA-27-1831	4	98	Treatment	Chemotherapy		Cisplatin	03	140	mg		Adjuvant				IV		No	420	mg											
TCGA-27-1831	39	84	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-1832	0	300	Treatment	Hormone Therapy		Dexamethasone			mg/day		Adjuvant						No	8	mg/day											
TCGA-27-1832	207	207	Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	1200	mg											
TCGA-27-1832	23	207	Treatment	Chemotherapy		Temozolomide	3		mg		Adjuvant				PO		No	3600	mg											
TCGA-27-1832	54	54	Treatment	Radiation Therapy		Radiation 1					Adjuvant														No	External Beam				
TCGA-27-1833	171	725	Treatment	Chemotherapy		Procarbazine	06		mg		Adjuvant				OTHER		No	1300	mg											
TCGA-27-1833	171	596	Treatment	Chemotherapy		Cisplatin	04		mg		Adjuvant				OTHER		No	320	mg											
TCGA-27-1833	-6	737	Treatment	Hormone Therapy		Dexamethasone			mg/day		Adjuvant						No	8	mg/day											
TCGA-27-1833	171	359	Treatment	Chemotherapy		Fotemustine	06		mg		Adjuvant				OTHER		No	208	mg											
TCGA-27-1833	171	596	Treatment	Chemotherapy		Temozolomide	04		mg		Adjuvant				OTHER		No	3500	mg											
TCGA-27-1833	63	94	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-1834	15	168	Treatment	Chemotherapy		Cisplatin	5		mg		Adjuvant				OTHER		No	320	mg											
TCGA-27-1834	15	168	Treatment	Chemotherapy		Temozolomide	5		mg		Adjuvant				OTHER		No	6250	mg											
TCGA-27-1834	352	540	Treatment	Chemotherapy		Fotemustine	06		mg		Adjuvant				OTHER		No	1200	mg											
TCGA-27-1834	-5	1233	Treatment	Hormone Therapy		Dexamethasone			mg		Adjuvant						No	7302	mg											
TCGA-27-1834	352	540	Treatment	Chemotherapy		Procarbazine	06		mg		Adjuvant				OTHER		No	1248	mg											
TCGA-27-1834	352	662	Treatment	Chemotherapy		Temozolomide			mg		Adjuvant				PO		Yes	35000	mg											
TCGA-27-1834	27	64	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-1835	4	158	Treatment	Chemotherapy		Temozolomide	03	300	mg		Adjuvant				PO		No	4300	mg											
TCGA-27-1835	208	208	Treatment	Chemotherapy		Fluorouracil + Tegafur	01	12	ml		Recurrence				IV		No	12	ml											
TCGA-27-1835	-7	648	Treatment	Hormone Therapy		Dexamethasone		4	mg		Adjuvant				PO		No	1308	mg											
TCGA-27-1835	-7	648	Treatment	Hormone Therapy		Levetiracetam		1000	mg		Adjuvant				PO		No	654000	mg											
TCGA-27-1835	206	462	Treatment	Chemotherapy		Potassium Chloride	05	300	mg		Recurrence				PO		No	8400	mg											
TCGA-27-1835	270	270	Treatment	Chemotherapy		Carmustine	01	200	mg		Recurrence				IV		No	200	mg											
TCGA-27-1835	2	3	Treatment	Chemotherapy		Cisplatin	01	160	mg		Adjuvant				IV		No	160	mg											
TCGA-27-1835	55	100	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-1836	245	399	Treatment	Chemotherapy		Polychlorinated Biphenyl	5	500	mg		Adjuvant				PO		No	3550	mg											
TCGA-27-1836	655	760	Treatment	Chemotherapy		Irinotecan	7	200	mg		Adjuvant				IV		No	1440	mg											
TCGA-27-1836	120	181	Treatment	Chemotherapy		Temozolomide	3	200	mg		Adjuvant				PO		No	8400	mg											
TCGA-27-1836	472	562	Treatment	Chemotherapy		Temozolomide	3	200	mg		Adjuvant				PO		No	8400	mg											
TCGA-27-1836	247	399	Treatment	Chemotherapy		Fotemustine	5	160	mg		Adjuvant				IV		No	896	mg											
TCGA-27-1836	-7	914	Treatment	Hormone Therapy		Dexamethasone		24	mg		Adjuvant				PO		No	22080	mg											
TCGA-27-1836	-7	914	Treatment	Hormone Therapy		Valproic Acid		900	mg		Adjuvant				PO		No	828000	mg											
TCGA-27-1836	655	760	Treatment	Chemotherapy		Bevacizumab	8	800	mg		Adjuvant				IV		No	6720	mg											
TCGA-27-1836	48	90	Treatment	Chemotherapy		Temozolomide	7	140	mg		Adjuvant				PO		No	5880	mg											
TCGA-27-1836	48	90	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-1837	-1	148	Treatment	Chemotherapy		Cisplatin	05	160	mg		Adjuvant				IV		No	800	mg											
TCGA-27-1837	35	106	Treatment	Chemotherapy		Doxorubicin	04	4	mg		Adjuvant				OTHER		No	16	mg											
TCGA-27-1837	1	153	Treatment	Chemotherapy		Temozolomide	05	350	mg		Adjuvant				PO		No	8750	mg											
TCGA-27-1837	-6	427	Treatment	Hormone Therapy		Dexamethasone		4	mg		Adjuvant				PO		No	2592	mg											
TCGA-27-1837	40	44	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-27-1837	68	72	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-27-1838	-11	350	Treatment	Hormone Therapy		Dexamethasone		4	mg		Adjuvant				OTHER		No	2214	mg											
TCGA-27-1838	-11	350	Treatment	Hormone Therapy		Oxcarbazepine		600	mg		Adjuvant				PO		No	216600	mg											
TCGA-27-1838	3	7	Treatment	Chemotherapy		Temozolomide	1	300	mg		Adjuvant				PO		No	1500	mg											
TCGA-27-1838	1	2	Treatment	Chemotherapy		Cisplatin	1	140	mg		Adjuvant				IV		No	140	mg											
TCGA-27-1838	71	102	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-2518	627	700	Treatment	Chemotherapy		Fotemustine	03	180	mg		Recurrence				IV		No	580	mg											
TCGA-27-2518	55	753	Treatment	Hormone Therapy		Dexamethasone		8	mg		Adjuvant				OTHER		No	5576	mg											
TCGA-27-2518	55	753	Treatment	Hormone Therapy		Levetiracetam		1500	mg		Adjuvant				PO		No	1045500	mg											
TCGA-27-2518	627	700	Treatment	Chemotherapy		Potassium Chloride	03	300	mg		Recurrence				PO		No	3600	mg											
TCGA-27-2518	20	107	Treatment	Chemotherapy		Cisplatin	03	160	mg		Adjuvant				IV		No	500	mg											
TCGA-27-2518	22	182	Treatment	Chemotherapy		Temozolomide	05	350	mg		Adjuvant				PO		No	8750	mg											
TCGA-27-2518	38	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-2519	133	259	Treatment	Chemotherapy		Temozolomide	5	300	mg		Adjuvant				PO		No	7500	mg											
TCGA-27-2519	-10		Treatment	Hormone Therapy		Levetiracetam		1500	mg		Adjuvant				PO		Yes		mg											
TCGA-27-2519	49	95	Treatment	Chemotherapy		Temozolomide	1	140	mg		Adjuvant				PO		No	6440	mg											
TCGA-27-2519	-10		Treatment	Hormone Therapy		Dexamethasone		16	mg		Adjuvant				PO		Yes		mg											
TCGA-27-2519	302		Treatment	Chemotherapy		Fotemustine	03	130	mg		Adjuvant				IV		Yes	390	mg											
TCGA-27-2519	49	95	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-2521	-15		Treatment	Hormone Therapy		Levetiracetam		1000	mg		Adjuvant				PO		Yes		mg											
TCGA-27-2521	104		Treatment	Chemotherapy		Temozolomide	8	350	mg		Adjuvant				PO		Yes	14000	mg											
TCGA-27-2521	-15		Treatment	Hormone Therapy		Dexamethasone		2	mg		Adjuvant				PO		Yes		mg											
TCGA-27-2521	43	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-27-2523	60	380	Treatment	Chemotherapy		Temozolomide	10	300	mg		Adjuvant				PO		No	15000	mg											
TCGA-27-2523	-6	489	Treatment	Hormone Therapy		Dexamethasone		8	mg		Adjuvant				PO		No	3960	mg											
TCGA-27-2523	11	11	Treatment	Chemotherapy		Lomustine	01	160	mg		Adjuvant				PO		No	160	mg											
TCGA-27-2523	-6	489	Treatment	Hormone Therapy		Phenytoin		300	mg		Adjuvant				PO		No	148500	mg											
TCGA-27-2523	10	59	Treatment	Chemotherapy		Cisplatin	02	90	mg		Adjuvant				IV		No	315	mg											
TCGA-27-2523	97	386	Treatment	Chemotherapy		Erlotinib	10	150	mg		Adjuvant				PO		No	1500	mg											
TCGA-27-2523	55	60	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-27-2523	29	36	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-27-2524	-6	-6	Treatment	Chemotherapy		Carmustine		8	{wafer}		Adjuvant				OTHER		No	61.6	{wafer}											
TCGA-27-2524	-6	231	Treatment	Hormone Therapy		Dexamethasone		4	mg		Adjuvant				OTHER		No	948	mg											
TCGA-27-2524	-6	231	Treatment	Hormone Therapy		Oxcarbazepine		600	mg		Adjuvant				PO		No	142200	mg											
TCGA-27-2524	58	119	Treatment	Chemotherapy		Temozolomide	03	300	mg		Adjuvant				PO		No	7500	mg											
TCGA-27-2524	82	86	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-27-2524	54	61	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-27-2526	-6	87	Treatment	Hormone Therapy		Dexamethasone		8	mg		Adjuvant				OTHER		No	744	mg											
TCGA-27-2527	-7	438	Treatment	Hormone Therapy		Valproic Acid		1000	mg		Adjuvant				PO		No	444000	mg											
TCGA-27-2527	-7	438	Treatment	Hormone Therapy		Dexamethasone		8	mg		Adjuvant				PO		No	3552	mg											
TCGA-27-2527	14	16	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		9	2250	No	External Beam	cgy			
TCGA-27-2527	36	38	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		9	2250	No	External Beam	cgy			
TCGA-27-2528	445	465	Treatment	Chemotherapy		Temozolomide	01	140	mg		Recurrence				PO		No	1960	mg											
TCGA-27-2528	-12	480	Treatment	Hormone Therapy		Levetiracetam		1000	mg		Adjuvant				PO		No	603500	mg											
TCGA-27-2528	-2	150	Treatment	Chemotherapy		Cisplatin	04	60	mg		Adjuvant				IV		No	510	mg											
TCGA-27-2528	-12	480	Treatment	Hormone Therapy		Dexamethasone		8	mg		Adjuvant				PO		No	3928	mg											
TCGA-27-2528	0	161	Treatment	Chemotherapy		Temozolomide	04	300	mg		Adjuvant				PO		No	6000	mg											
TCGA-27-2528	14	47	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-28-1747	25	36	Treatment	Chemotherapy		Temozolomide	01	160	mg		Adjuvant				PO		No		mg											
TCGA-28-1747	27	36	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		7	1260	No	External Beam	cgy			
TCGA-28-1749	19	159	Treatment	Chemotherapy		Temozolomide	05		mg		Adjuvant				PO		No	7560	mg											
TCGA-28-1749	19	159	Treatment	Chemotherapy		Temozolomide	05		mg		Adjuvant				PO		No	3800	mg											
TCGA-28-1749	19	159	Treatment	Chemotherapy		Temozolomide	05		mg		Adjuvant				PO		No	4400	mg											
TCGA-28-1749	19	63	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-28-1750	10	116	Treatment	Chemotherapy		Temozolomide	03		mg		Adjuvant				PO		No	5040	mg											
TCGA-28-1750	10	116	Treatment	Chemotherapy		Temozolomide	03		mg		Adjuvant				PO		No	1700	mg											
TCGA-28-1750	10	116	Treatment	Chemotherapy		Temozolomide	03		mg		Adjuvant				PO		No	1250	mg											
TCGA-28-1750	10	53	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		32	9700	No	External Beam	cgy			
TCGA-28-1750	127	134	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		5	2500	No	External Beam	cgy			
TCGA-28-1751	14	208	Treatment	Chemotherapy		Temozolomide	03		mg		Adjuvant				PO		No	2600	mg											
TCGA-28-1751	14	208	Treatment	Chemotherapy		Temozolomide	03		mg		Adjuvant				PO		No	2100	mg											
TCGA-28-1751	14	208	Treatment	Chemotherapy		Temozolomide	03		mg		Adjuvant				PO		No	6300	mg											
TCGA-28-1751	114	142	Treatment	Immunotherapy		Dc Vax (Dendritic Cell Vaccine)					Adjuvant				OTHER		No	3												
TCGA-28-1751	14	58	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		33	5940	No	External Beam	cgy			
TCGA-28-1752	11	272	Treatment	Chemotherapy		Temozolomide	05		mg		Adjuvant				PO		No	1800	mg											
TCGA-28-1752	11	272	Treatment	Chemotherapy		Temozolomide	05		mg		Adjuvant				PO		No	3000	mg											
TCGA-28-1752	11	272	Treatment	Chemotherapy		Temozolomide	05		mg		Adjuvant				PO		No	5880	mg											
TCGA-28-1752	105	132	Treatment	Immunotherapy		Dc Vax (Dendritic Cell Vaccine)					Adjuvant				OTHER		No	3												
TCGA-28-1752	11	272	Treatment	Chemotherapy		Temozolomide	05		mg		Adjuvant				PO		No	1440	mg											
TCGA-28-1752	12	52	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-28-1753	11	11	Treatment	Radiation Therapy		Radiation 1					Adjuvant	To The 50% Is Dose Line, The Patient Will Recieve Further Treatment In Puerto Rico, External Beam Radiation And Temodar Is Planned.									Primary Tumor Field		1	1400	No	Other	cgy			
TCGA-28-1755	15		Treatment	Chemotherapy		Temozolomide	01		mg		Adjuvant				PO		No	5040	mg											
TCGA-28-1755	16	43	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		20	4000	No	External Beam	cgy			
TCGA-28-1756	21	69	Treatment	Chemotherapy		Temozolomide		160	mg		Adjuvant				PO		No		mg											
TCGA-28-1756	25	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam				
TCGA-28-1756	10	10	Treatment	Radiation Therapy		Radiation 2					Adjuvant	To 50% Isodoc Line Which Encompassed The Tumor									Primary Tumor Field		1	1500	No	Other	cgy			
TCGA-28-2502	12	15	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		4	800	No	External Beam	cgy			
TCGA-28-2506	107	135	Treatment	Immunotherapy		Tumor Vaccine Nos		1.1	ml		Adjuvant				OTHER		No		ml											
TCGA-28-2506	177		Treatment	Targeted Molecular Therapy		Afatinib		40	mg		Progression				PO		Yes		mg											
TCGA-28-2506	27	72	Treatment	Chemotherapy		Temozolomide		100	mg/m2		Adjuvant				PO		No		mg/m2											
TCGA-28-2506	27	69	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-28-2509	33		Treatment	Chemotherapy		Temozolomide		75	mg/m2		Adjuvant				PO		Yes		mg/m2											
TCGA-28-2509	26		Treatment	Targeted Molecular Therapy		Cilengitide		2000	mg/day		Adjuvant				IV		Yes		mg/day											
TCGA-28-2509	33	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		8	1600	No	External Beam	cgy			
TCGA-28-2509	33	62	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		22	4400	No	External Beam	cgy			
TCGA-28-2513	44		Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg		Recurrence				IV		Yes	460	mg											
TCGA-28-2513	44		Treatment	Chemotherapy		Temozolomide		280	mg/day		Recurrence				PO		Yes		mg/day											
TCGA-28-2513	28	57	Treatment	Chemotherapy		Temozolomide		280	mg/day		Adjuvant				PO		No		mg/day											
TCGA-28-2513	28	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-28-2513	85	85	Treatment	Radiation Therapy		Radiation 2					Progression	To The 50/ Isdose Line									Local Recurrence		1	1700	No	Other	cgy			
TCGA-28-2514	29		Treatment	Chemotherapy		Temozolomide		75	mg/m2		Adjuvant				PO		Yes		mg/m2											
TCGA-28-2514	26	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-28-5204	9	448	Treatment	Chemotherapy		Temozolomide		140	mg	01	Adjuvant				PO		No	8160	mg											
TCGA-28-5204	9	448	Treatment	Chemotherapy		Temozolomide		140	mg		Adjuvant				PO		No	8160	mg											
TCGA-28-5204	9	52	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-28-5204	9	52	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-28-5208	11	49	Treatment	Chemotherapy		Temozolomide	01	140	mg	01	Adjuvant				PO		No	5320	mg											
TCGA-28-5208	11	49	Treatment	Chemotherapy		Temozolomide	01	140	mg		Adjuvant				PO		No	5320	mg											
TCGA-28-5208	287	435	Treatment	Chemotherapy		Bevacizumab	05	10	mg/kg	03	Recurrence				IV		No													
TCGA-28-5208	287	435	Treatment	Chemotherapy		Bevacizumab	05	10			Recurrence				IV		No													
TCGA-28-5208	149	285	Treatment	Chemotherapy		Temozolomide	05	390	mg	02	Recurrence				PO		No	9750	mg											
TCGA-28-5208	287	435	Treatment	Chemotherapy		Irinotecan	05				Recurrence						No													
TCGA-28-5208	149	285	Treatment	Chemotherapy		Temozolomide	05	390	mg		Recurrence				PO		No	9750	mg											
TCGA-28-5208	287	435	Treatment	Chemotherapy		Irinotecan	05			03	Recurrence						No													
TCGA-28-5208	13	54	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-28-5208	13	54	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-28-5208	159	159	Treatment	Radiation Therapy		Radiation 3					Recurrence										Local Recurrence		1	1800	No	Other	cgy			
TCGA-28-5208	159	159	Treatment	Radiation Therapy		Radiation 4					Recurrence										Local Recurrence	2	1	1800	No	Other	cgy			
TCGA-28-5211	-1	57	Treatment	Chemotherapy		Temozolomide	01	140	mg	01	Adjuvant				PO		No	8360	mg											
TCGA-28-5211	-1	57	Treatment	Chemotherapy		Temozolomide	01	140	mg		Adjuvant				PO		No	8360	mg											
TCGA-28-5211	239	307	Treatment	Chemotherapy		Bevacizumab	02			02	Recurrence				IV		No													
TCGA-28-5211	239	307	Treatment	Chemotherapy		Bevacizumab	02				Recurrence						No													
TCGA-28-5211	239	307	Treatment	Chemotherapy		Irinotecan	02			02	Recurrence						No													
TCGA-28-5211	239	307	Treatment	Chemotherapy		Irinotecan	02				Recurrence						No													
TCGA-28-5211	9	57	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6600	No	External Beam	cgy			
TCGA-28-5211	9	57	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	6600	No	External Beam	cgy			
TCGA-28-5213	11		Treatment	Chemotherapy		Temozolomide		1800	mg/m2/day		Adjuvant				PO		Yes		mg/kg/day											
TCGA-28-5213	11		Treatment	Chemotherapy		Temozolomide		140	mg/m2/day		Adjuvant				PO		Yes		mg/m2/day											
TCGA-28-5213	9	50	Treatment	Chemotherapy		Temozolomide											No													
TCGA-28-5213	11		Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			6000		External Beam	cgy			
TCGA-28-5213	11		Treatment	Radiation Therapy		Radiation 2					Adjuvant	Patient Moved Back To Mexico									Primary Tumor Field			6000		External Beam	cgy			
TCGA-28-5213	11	53	Treatment	Radiation Therapy		Radiation 3															Primary Tumor Field		30	6000	No	External	cgy			
TCGA-28-5214	20		Treatment	Chemotherapy		Temozolomide	02	1750	mg/m2/day	01	Adjuvant				PO		Yes		mg/m2/day											
TCGA-28-5214	20		Treatment	Chemotherapy		Temozolomide	02	1750	mg/m2/day		Adjuvant				PO		Yes		mg/m2/day											
TCGA-28-5214	262		Treatment	Chemotherapy		Bevacizumab		10	mg/kg	02	Recurrence				IV		Yes													
TCGA-28-5214	262		Treatment	Chemotherapy		Irinotecan				02	Recurrence				IV		Yes													
TCGA-28-5214	262		Treatment	Chemotherapy		Bevacizumab		10	mg/kg		Recurrence				IV		Yes		mg/kg											
TCGA-28-5214	262		Treatment	Chemotherapy		Irinotecan					Recurrence				IV		Yes													
TCGA-28-5214	20	62	Treatment	Chemotherapy		Temozolomide											No													
TCGA-28-5214	20		Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1			Yes	External Beam				
TCGA-28-5214	20		Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field				Yes	External Beam				
TCGA-28-5214	324	324	Treatment	Radiation Therapy		Radiation 3					Recurrence										Local Recurrence	2	1	1600	No	Other	cgy			
TCGA-28-5214	324	324	Treatment	Radiation Therapy		Radiation 4					Recurrence										Local Recurrence		1	1600	No		cgy			
TCGA-28-5214	20	67	Treatment	Radiation Therapy		Radiation 5															Primary Tumor Field		30	6000	No	External	cgy			
TCGA-28-5216	29	70	Treatment	Chemotherapy		Temozolomide	10	140	mg	01	Adjuvant				PO		No	5880	mg											
TCGA-28-5216	29	70	Treatment	Chemotherapy		Temozolomide	10	140	mg		Adjuvant				PO		No	5880	mg											
TCGA-28-5216	29	70	Treatment	Not Specified		Temozolomide											No													
TCGA-28-5216	30	72	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-28-5216	30	72	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-28-5216	30	72	Treatment	Radiation Therapy		Radiation 3															Primary Tumor Field		30	6000	No	External	cgy			
TCGA-28-5218	68		Treatment	Chemotherapy		Temozolomide		100	mg	01	Adjuvant				PO		No													
TCGA-28-5218	68		Treatment	Chemotherapy		Temozolomide		100	mg		Adjuvant				PO		No		mg											
TCGA-28-5218	16	29	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	15	3000	No	External Beam	cgy			
TCGA-28-5218	16	29	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		15	3000	No	External Beam	cgy			
TCGA-28-5220	138		Treatment	Not Specified		Temozolomide											No													
TCGA-28-6450	25	41	Treatment	Chemotherapy		Temozolomide	03	123	mg	01	Adjuvant				PO		No	2125	mg											
TCGA-28-6450	25	41	Treatment	Chemotherapy		Temozolomide	03	125	mg		Adjuvant				PO		No	2125	mg											
TCGA-28-6450	26	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-28-6450	26	67	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-1970	28	67	Treatment	Chemotherapy		Temozolomide		170	mg		Adjuvant				PO		No	6800	mg											
TCGA-32-1970	28	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	600	No	External Beam	cgy			
TCGA-32-1973	521	542	Treatment	Chemotherapy		Temozolomide	1	150	mg		Progression				PO		No		mg											
TCGA-32-1973	521	542	Treatment	Chemotherapy		Afatinib	1				Progression				PO		No													
TCGA-32-1973	549	631	Treatment	Chemotherapy		Bevacizumab	6	949			Progression				IV		No													
TCGA-32-1973	549	631	Treatment	Chemotherapy		Irinotecan	6	125			Progression				IV		No													
TCGA-32-1973	99	417	Treatment	Chemotherapy		Temozolomide	12	390			Adjuvant				PO		No													
TCGA-32-1973	22	64	Treatment	Chemotherapy		Temozolomide		300			Adjuvant				PO		No													
TCGA-32-1973	23	32	Treatment	Chemotherapy		Motexafin Gadolinium	2	5	mg/kg		Adjuvant				IP	IV	No		mg/kg											
TCGA-32-1973	23	64	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-1986	126	139	Treatment	Chemotherapy		Temozolomide	1	150	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-1986	126	156	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		18	4500	No	External Beam	cgy			
TCGA-32-1987	68	68	Treatment	Chemotherapy		Carmustine		5	{wafer}		Progression				OTHER		No		{wafer}											
TCGA-32-1987	26	67	Treatment	Chemotherapy		Temozolomide	1		mg/day		Adjuvant				PO		No	120	mg/day											
TCGA-32-1987	130	134	Treatment	Chemotherapy		Temozolomide	1	250	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-1987	222		Treatment	Chemotherapy		Bevacizumab			mg/kg		Progression				IV		No		mg/kg											
TCGA-32-1987	26	67	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	5800	No	External Beam	cgy			
TCGA-32-1991	22	65	Treatment	Chemotherapy		Temozolomide	1	165	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-1991	0	0	Treatment	Chemotherapy		Carmustine		5	{wafer}		Adjuvant				PO		No		{wafer}											
TCGA-32-1991	94	98	Treatment	Chemotherapy		Temozolomide	1	330	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-1991	124	341	Treatment	Chemotherapy		Temozolomide	8	425	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-1991	94	98	Treatment	Chemotherapy		Temozolomide	1	330	mg/day		Adjuvant						No		mg/day											
TCGA-32-1991	23	65	Treatment	Chemotherapy		Motexafin Gadolinium	06	05	mg/kg		Adjuvant				IV		No		mg/kg											
TCGA-32-1991	23	65	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-2491	117	122	Treatment	Chemotherapy		Temozolomide	1	200	mg/m2		Progression				PO		No		mg/m2											
TCGA-32-2491	18	59	Treatment	Chemotherapy		Temozolomide		160	mg/m2		Adjuvant				PO		No	6720	mg/m2											
TCGA-32-2491	19	61	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-2494	620	632	Treatment	Chemotherapy		Temozolomide	1	140	mg/day		Progression				PO		No		mg/day											
TCGA-32-2494	20	62	Treatment	Chemotherapy		Temozolomide		140	mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-32-2494	620	620	Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Progression				IV		No	10	mg/kg											
TCGA-32-2494	90	94	Treatment	Chemotherapy		Temozolomide	1	270	mg/m2		Adjuvant				PO		No	150	mg/m2											
TCGA-32-2494	488	550	Treatment	Chemotherapy		Temozolomide	4	160	mg/day		Progression				PO		No		mg/day											
TCGA-32-2494	488	550	Treatment	Targeted Molecular Therapy		Bevacizumab		600	mg		Progression				PO		No		mg											
TCGA-32-2494	120	403	Treatment	Chemotherapy		Temozolomide	11	360	mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-32-2494	21	62	Treatment	Radiation Therapy		Radiation 1					Adjuvant												30	354	No	Radioisotope				
TCGA-32-2494	21	62	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-2494	501	518	Treatment	Radiation Therapy		Radiation 3					Progression										Local Recurrence		12	3900	No	External Beam	cgy			
TCGA-32-2495	252	252	Treatment	Chemotherapy		Carmustine		5	{wafer}		Progression				OTHER		No		{wafer}											
TCGA-32-2495	34	75	Treatment	Chemotherapy		Temozolomide	1	140			Adjuvant				PO		No													
TCGA-32-2495	278	429	Treatment	Chemotherapy		Temozolomide	5	380			Progression				PO		No													
TCGA-32-2495	103	107	Treatment	Chemotherapy		Temozolomide	1	290			Adjuvant				PO		No													
TCGA-32-2495	131	192	Treatment	Chemotherapy		Temozolomide	3	380			Adjuvant				PO		No													
TCGA-32-2495	275	275	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		1	1200	No	Other	cgy			
TCGA-32-2495	34	75	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	5400	No	External Beam	cgy			
TCGA-32-2615	26	65	Treatment	Chemotherapy		Temozolomide		160	mg/day		Adjuvant				PO		No	160	mg/day											
TCGA-32-2615	96	100	Treatment	Chemotherapy		Temozolomide	1		mg/day		Adjuvant				PO		No	300	mg/day											
TCGA-32-2615	301		Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Recurrence				IP	IV	Yes	10	mg/kg											
TCGA-32-2615	285	285	Treatment	Chemotherapy		Carmustine			{wafer}						OTHER		No		{wafer}											
TCGA-32-2615	0	0	Treatment	Chemotherapy		Carmustine			{wafer}		Adjuvant				OTHER		No		{wafer}											
TCGA-32-2615	161	273	Treatment	Chemotherapy		Temozolomide	4		mg/day		Adjuvant				OTHER		No	155	mg/day											
TCGA-32-2615	301		Treatment	Targeted Molecular Therapy		Bevacizumab			mg/kg		Recurrence				IP	IV	Yes	10	mg/kg											
TCGA-32-2615	285	285	Treatment	Chemotherapy		Carmustine					Recurrence				OTHER		No													
TCGA-32-2615	313	313	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence		1	146	No	Other	cgy			
TCGA-32-2616	30	51	Treatment	Targeted Molecular Therapy		Motexafin Gadolinium			mg		Adjuvant				IV		No	50167	mg											
TCGA-32-2616	29	71	Treatment	Chemotherapy		Temozolomide		75	mg		Adjuvant				PO		No	5590	mg											
TCGA-32-2616	101	105	Treatment	Chemotherapy		Temozolomide	1	270	mg		Adjuvant				PO		No	1350	mg											
TCGA-32-2616	129	161	Treatment	Chemotherapy		Temozolomide	2	200	mg		Adjuvant				PO		No	360	mg											
TCGA-32-2616	30	72	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-2616	189	203	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		10	3000	No	External Beam	cgy			
TCGA-32-2634	0	0	Treatment	Chemotherapy		Carmustine			{wafer}						OTHER		No		{wafer}											
TCGA-32-2634	17	59	Treatment	Chemotherapy		Temozolomide		200	mg		Adjuvant				PO		Yes	160	mg											
TCGA-32-2634	108		Treatment	Chemotherapy		Temozolomide	11	200	mg		Other, Specify In Notes				PO		Yes		mg											
TCGA-32-2634	17	59	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-2638	26	68	Treatment	Chemotherapy		Temozolomide			mg/day		Adjuvant				PO		No	190	mg/day											
TCGA-32-2638	49	133	Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg/kg		Adjuvant				IV		No		mg/kg											
TCGA-32-2638	110	114	Treatment	Chemotherapy		Temozolomide			mg/day		Adjuvant				PO		No	380	mg/day											
TCGA-32-2638	26	68	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-4208	174		Treatment	Chemotherapy		Temozolomide		300	mg/day		Adjuvant				PO		Yes		mg/day											
TCGA-32-4208	146	150	Treatment	Chemotherapy		Temozolomide		300	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-4208	41	84	Treatment	Chemotherapy		Temozolomide	1	140	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-4208	41	85	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-4209	41	85	Treatment	Chemotherapy		Temozolomide	1		mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-32-4209	503	532	Treatment	Chemotherapy		Lomustine	02	100	mg/kg	02	Progression				PO		No	200	mg											
TCGA-32-4209	503	553	Treatment	Targeted Molecular Therapy		Bevacizumab	04	10	mg/kg	03	Progression				IV		No	400	mg											
TCGA-32-4209	41	85	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-4209	461	461	Treatment	Radiation Therapy		Radiation 2					Recurrence										Primary Tumor Field	3	1	1400	No	Other	cgy			
TCGA-32-4209	365	385	Treatment	Radiation Therapy		Radiation 3					Progression										Primary Tumor Field	2	13	3900	No	External Beam	cgy			
TCGA-32-4209	556	556	Treatment	Radiation Therapy		Radiation 4					Palliative										Regional Site	4	4	3900	No	Other	cgy			
TCGA-32-4211	127	131	Treatment	Chemotherapy		Temozolomide	1	440	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-4211	24	65	Treatment	Chemotherapy		Temozolomide	1	160	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-4211	93	97	Treatment	Chemotherapy		Temozolomide	1	330	mg/day		Adjuvant				PO		No		mg/day											
TCGA-32-4211	24	65	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-4213	130	135	Treatment	Chemotherapy		Temozolomide			mg/day		Adjuvant				PO		No	390	mg/day											
TCGA-32-4213	155	289	Treatment	Chemotherapy		Temozolomide	5		mg/day		Adjuvant				PO		No	400	mg/day											
TCGA-32-4213	24	107	Treatment	Chemotherapy		Temozolomide			mg/day		Adjuvant				PO		No	130	mg/day											
TCGA-32-4213	561		Treatment	Targeted Molecular Therapy		Bevacizumab	04	944	mg	04	Progression				IV		Yes	3776	mg											
TCGA-32-4213	351	351	Treatment	Radiation Therapy		Radiation 1					Progression										Local Recurrence		1	71	No	Radioisotope	mci			
TCGA-32-4213	24	67	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-4719	31	70	Treatment	Chemotherapy		Temozolomide		140	mg/m2		Adjuvant				PO		No	75	mg/m2											
TCGA-32-4719	88	245	Treatment	Chemotherapy		Temozolomide	6	380	mg/m2		Adjuvant				PO		No	200	mg/m2											
TCGA-32-4719	31	70	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-5222	33	77	Treatment	Chemotherapy		Temozolomide	4	140	mg		Adjuvant				PO		No	5880	mg											
TCGA-32-5222	34	77	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-32-5222	193	193	Treatment	Radiation Therapy		Radiation 2					Progression										Primary Tumor Field	2	1	2800	No	Other	cgy			
TCGA-41-2571	22	25	Treatment	Chemotherapy		Temozolomide	1	160	mg		Palliative				PO		No	640	mg											
TCGA-41-2572	133	351	Treatment	Chemotherapy		Bevacizumab	13	1200	mg		Progression				IV		No	15600	mg											
TCGA-41-2572	34	76	Treatment	Targeted Molecular Therapy		Temozolomide		180	mg		Other, Specify In Notes				PO		No	7740	mg											
TCGA-41-2572	34	76	Treatment	Radiation Therapy		Radiation 1					Other, Specify In Notes	Concurrent Chemoradiation									Primary Tumor Field		28	5040	No	External Beam	cgy			
TCGA-41-2572	78	80	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		3	1800	No	Other	cgy			
TCGA-41-2573	171		Treatment	Targeted Molecular Therapy		Bevacizumab		10	mg/kg		Progression				IV		Yes		mg/kg											
TCGA-41-2573	100	142	Treatment	Chemotherapy		Temozolomide	1	160	mg		Adjuvant				PO		No	6880	mg											
TCGA-41-2573	127	142	Treatment	Targeted Molecular Therapy		Iniparib					Adjuvant				IV		No													
TCGA-41-2573	29	71	Treatment	Chemotherapy		Temozolomide	1	160	mg		Adjuvant				PO		No	6720	mg											
TCGA-41-2573	29	71	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-41-2575	95	145	Treatment	Chemotherapy		Temozolomide	1	140	mg		Adjuvant				PO		No	7140	mg											
TCGA-41-2575	166	166	Treatment	Targeted Molecular Therapy		Bevacizumab		800	mg		Progression				IV		No	800	mg											
TCGA-41-2575	95	145	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-41-2575	167	169	Treatment	Radiation Therapy		Radiation 2					Progression										Local Recurrence		3	1800	No	External Beam	cgy			
TCGA-41-3393	51	95	Treatment	Chemotherapy		Temozolomide	1	120	mg		Other, Specify In Notes				PO		No	5040	mg											
TCGA-41-3393	51	95	Treatment	Radiation Therapy		Radiation 1					Other, Specify In Notes	Concurrent Chemoradiation									Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-41-3915	27	71	Treatment	Chemotherapy		Temozolomide	1	160	mg		Other, Specify In Notes				PO		No	6880	mg											
TCGA-41-3915	115		Treatment	Chemotherapy		Temozolomide	3	320	mg		Adjuvant				PO		Yes	5200	mg											
TCGA-41-3915	202	289	Treatment	Chemotherapy		Temozolomide	04	400	mg	02	Adjuvant				PO		No	8000	mg											
TCGA-41-3915	27	71	Treatment	Radiation Therapy		Radiation 1					Other, Specify In Notes	Concurrent Chemoradiation									Primary Tumor Field		30	6000	No	Other	cgy			
TCGA-41-5651	345		Treatment	Targeted Molecular Therapy		Bevacizumab		800	mg		Recurrence				IV		Yes	800	mg											
TCGA-41-5651	31	77	Treatment	Chemotherapy		Temozolomide	01	140	mg		Adjuvant				PO		No	6580	mg											
TCGA-41-5651	105	195	Treatment	Chemotherapy		Temozolomide	04	350	mg		Adjuvant				PO		No	6600	mg											
TCGA-41-5651	231		Treatment	Chemotherapy		Carmustine	01		{wafer}		Recurrence				OTHER		No		{wafer}											
TCGA-41-5651	359	387	Treatment	Targeted Molecular Therapy		Bevacizumab	03	850	mg	04	Recurrence				IV		No	2550	mg											
TCGA-41-5651	31	77	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-41-5651	366	368	Treatment	Radiation Therapy		Radiation 2					Recurrence										Primary Tumor Field	2	3	2400	No	Other	cgy			
TCGA-41-6646	40	81	Treatment	Chemotherapy		Temozolomide	01	160	mg		Adjuvant				PO		No	6720	mg											
TCGA-41-6646	112	196	Treatment	Chemotherapy		Temozolomide	03	320	mg		Adjuvant				PO		No	5600	mg											
TCGA-41-6646	40	82	Treatment	Radiation Therapy		Radiation 1					Adjuvant	Pt Treated With Concurrent Chemo Temozolomide And Radiation Therapy									Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-4W-AA9R	30	72	Treatment	Radiation Therapy		Radiation 1															Primary Tumor Field			18	No	External				
TCGA-4W-AA9S	56	105	Treatment	Chemotherapy		Temozolomide							complete response				No			No										
TCGA-4W-AA9S	56	105	Treatment	Radiation Therapy		Radiation 1							complete response								Primary Tumor Field		25	55	No	External	gy			
TCGA-4W-AA9T	36		Treatment	Chemotherapy		Temozolomide											Yes			No										
TCGA-4W-AA9T	79	79	Treatment	Radiation Therapy		Radiation 1							complete response												No					
TCGA-74-6573	24	66	Treatment	Chemotherapy		Temozolomide	1	140	mg/day	1	Adjuvant				PO		No	6020	mg											
TCGA-74-6573	24	66	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	35	5800	No	External Beam	cgy			
TCGA-74-6575	36	73	Treatment	Chemotherapy		Temozolomide	1	120	mg/day	1	Adjuvant				PO		No	4560	mg											
TCGA-74-6575	498		Treatment	Targeted Molecular Therapy		Bevacizumab	1	10	mg/kg	4	Recurrence				IV		Yes		mg/kg											
TCGA-74-6575	152	498	Treatment	Targeted Molecular Therapy		Bevacizumab	1	5	mg/kg	3	Recurrence				IV		No	255	mg/kg											
TCGA-74-6575	96	131	Treatment	Chemotherapy		Temozolomide	2	200	mg/day	2	Recurrence				PO		No	2000	mg											
TCGA-74-6575	28	76	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	33	5940	No	External Beam	cgy			
TCGA-74-6577	55	99	Treatment	Chemotherapy		Temozolomide	1	140	mg/day	1	Adjuvant				PO		No	6300	mg											
TCGA-74-6577	132		Treatment	Targeted Molecular Therapy		Bevacizumab	1	10	mg/kg	2	Progression				IV		Yes		mg/kg											
TCGA-74-6577	55	87	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Regional Site	1	25	4500	No	External Beam	cgy			
TCGA-74-6577	91	99	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Regional Site	2	8	1400	No	External Beam	cgy			
TCGA-74-6578	38	80	Treatment	Chemotherapy		Temozolomide	1	150	mg/day	1	Adjuvant				PO		No	6450	mg											
TCGA-74-6578	98	103	Treatment	Chemotherapy		Temozolomide	1	150	mg/day	2	Adjuvant				PO		No	750	mg											
TCGA-74-6578	222		Treatment	Targeted Molecular Therapy		Bevacizumab	1	10	mg/kg	3	Progression				IV		Yes	200	mg/kg											
TCGA-74-6578	38	80	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	30	6000	No	External Beam	cgy			
TCGA-74-6581	26	74	Treatment	Chemotherapy		Temozolomide	1	150	mg/day	1	Adjuvant				PO		No	7350	mg											
TCGA-74-6581	94		Treatment	Chemotherapy		Temozolomide	6	200	mg/m2/day	2	Adjuvant				PO		Yes	6000	mg/m2											
TCGA-74-6581	26	74	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field	1	33	5940	No	External Beam	cgy			
TCGA-74-6584	98		Treatment	Targeted Molecular Therapy		Bevacizumab	11	10	mg/m2	1	Progression				IV		Yes	110	mg/m2											
TCGA-74-6584	99		Treatment	Chemotherapy		Temozolomide	5	120	mg/day	2	Progression				PO		Yes	12600	mg											
TCGA-74-6584	21	65	Treatment	Chemotherapy		Temozolomide	1	150	mg/day	1	Adjuvant				PO		No	6750	mg											
TCGA-74-6584	95	95	Treatment	Radiation Therapy		Radiation 1					Progression										Regional Site	2	1	1000	No	External Beam	cgy			
TCGA-74-6584	21	65	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field	1	32	5760	No	External Beam	cgy			
TCGA-76-4926	83	115	Treatment	Chemotherapy		Temozolomide	02				Adjuvant						No													
TCGA-76-4931	40	71	Treatment	Radiation Therapy		Radiation 1					Recurrence										Primary Tumor Field				No	Other				
TCGA-76-4932	31	73	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-76-4935	11		Treatment	Chemotherapy		Bevacizumab		10	mg		Adjuvant				IV		Yes	590	mg											
TCGA-76-4935	176		Treatment	Chemotherapy		Temozolomide		250	mg		Adjuvant				PO		Yes		mg											
TCGA-76-6191	24	423	Treatment	Chemotherapy		Temozolomide			mg		Adjuvant				PO		No		mg											
TCGA-76-6191	269	423	Treatment	Chemotherapy		Bevacizumab		10	mg/kg		Adjuvant				IV		No		mg/kg											
TCGA-76-6191	356	370	Treatment	Radiation Therapy		Radiation 1					Recurrence										Local Recurrence		1	18	No	External Beam	cgy			
TCGA-76-6191	437	437	Treatment	Radiation Therapy		Radiation 2					Progression										Primary Tumor Field		1	18	No	Other	cgy			
TCGA-76-6191	24	86	Treatment	Radiation Therapy		Radiation 3					Adjuvant										Primary Tumor Field		23	46	No	External Beam	cgy			
TCGA-76-6192	39	75	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		26	52.0	No	External Beam				
TCGA-76-6193	9		Treatment	Chemotherapy		Temozolomide					Adjuvant				PO		No													
TCGA-76-6193	9		Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		60		No	External Beam	cgy			
TCGA-76-6280	27		Treatment	Chemotherapy		Temozolomide		150	mg		Adjuvant				PO		No		mg											
TCGA-76-6280	182	192	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		10	35	No	External Beam	cgy			
TCGA-76-6280	27	66	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		23	60	No	External Beam	cgy			
TCGA-76-6282	24	213	Treatment	Chemotherapy		Temozolomide		210	mg		Adjuvant				PO		No		mg											
TCGA-76-6282	320	374	Treatment	Chemotherapy		Bevacizumab	6	890	mg		Adjuvant				IV		No	5340	mg											
TCGA-76-6282	25	65	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			60	No	External Beam	cgy			
TCGA-76-6286	510	580	Treatment	Chemotherapy		Bevacizumab	06	990	mg		Progression				IV		No	5940	mg											
TCGA-76-6286	102		Treatment	Chemotherapy		Temozolomide		100	mg		Adjuvant				PO		No		mg											
TCGA-76-6286	250	250	Treatment	Radiation Therapy		Radiation 1					Progression										Primary Tumor Field		3.5	35	No	Radioisotope	cgy			
TCGA-76-6286	-278	67	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-76-6656	11		Treatment	Chemotherapy		Temozolomide		140	mg		Adjuvant				PO		No		mg											
TCGA-76-6656	42	89	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field			5940	No	External Beam	cgy			
TCGA-76-6657	48	80	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-76-6661	48	115	Treatment	Chemotherapy		Temozolomide			mg		Adjuvant				PO		No		mg											
TCGA-76-6661	48	87	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field				No	External Beam	cgy			
TCGA-76-6662	88	227	Treatment	Chemotherapy		Temozolomide		100	mg		Adjuvant				PO		No		mg											
TCGA-76-6662	254		Treatment	Chemotherapy		Carmustine	04	360	mg		Progression				IV		Yes	1440	mg											
TCGA-76-6662	22	65	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	External Beam	cgy			
TCGA-76-6663	44		Treatment	Chemotherapy		Temozolomide		320	mg		Adjuvant				PO		Yes		mg											
TCGA-76-6663	93	175	Treatment	Immunotherapy		Ict-107					Adjuvant						No													
TCGA-76-6663	44	86	Treatment	Radiation Therapy		Radiation 1					Adjuvant										Primary Tumor Field		30	60	No	Implants	cgy			
TCGA-76-6664	6		Treatment	Chemotherapy		Temozolomide		250	mg		Adjuvant				PO		Yes		mg											
TCGA-76-6664	43	223	Treatment	Chemotherapy		Bevacizumab	14	510	mg		Adjuvant				IV		No	7470	mg											
TCGA-81-5911	130	260	Treatment	Chemotherapy		Temozolomide	05	440	mg/day		Adjuvant				PO		No	11000	mg/day											
TCGA-81-5911	21	69	Treatment	Chemotherapy		Temozolomide	1	160	mg/day		Recurrence				PO		No	6720	mg/day											
TCGA-81-5911	104	108	Treatment	Chemotherapy		Temozolomide	1	330	mg/day		Adjuvant				PO		No	1650	mg/day											
TCGA-81-5911	347	351	Treatment	Radiation Therapy		Radiation 1					Recurrence										Primary Tumor Field		5	8000	No	Other	cgy			
TCGA-81-5911	34	75	Treatment	Radiation Therapy		Radiation 2					Adjuvant										Primary Tumor Field		30	6000	No	External Beam	cgy			
TCGA-87-5896	14	642	Treatment	Chemotherapy		Temozolomide							complete response				No			No										
TCGA-87-5896	3	64	Treatment	Radiation Therapy		Radiation 1							complete response								Primary Tumor Field			6000	No	External	cgy			
